NRG Oncology Summer 2022 Meeting

TABLE OF CONTENTS

- 2 Welcome Message
- 4 NRG Mission Statement/Edu Objectives
- 5 Continuing Education Information
- 6 Approved CME Session Credit List
- 7 Social Network/WIFI
- 8 Meeting App Information
- 9 Hotel Map - Hyatt Regency Chicago
- 10 Meeting Agenda

SESSIONS/SPECIAL EVENTS

- 17 Symposium - "Target Therapies - Focus on the Future"
- 19 PSC CTN/CRA Roundtable Sessions (All PSC Agendas on pg 75)
- 20 Early Career New Investigators (ECNI) Edu. Session
- 22 Translational Science Workshop
- 23 Social Media Workshop
- 25 NCORP Town Hall
- 27 NRG CC005 FORTE Protocol Workshop
- 29 Scientific Session - NRG Research Review
- 31 Pathology Committee Workshop

WORKSHOP AGENDAS (CME/Non-CME)

- 33 Brain Tumor Committee
- 34 Breast Cancer Committee
- 35 Canadian Members Subcommittee
- 36 Cancer Prevention & Control Cmte
- 37 Cancer Care Delivery Research Cmte (CCDR)
- 38 Cervix Vulvar Cancer Subcommittee
- 41 Developmental Therapeutics Cmte
- 45 Dev. Therapeutics Radiation Therapy (DTRT)
- 46 Genitourinary Cancer Cmte
- 49 GI - CRC Subcommittee
- 50 GI - Non-CRC Subcommittee
- 51 Gynecologic Cancer Committees
- 57 Head and Neck Cancer Committee
- 59 Head and Neck Surgical Subcommittee
- 60 Health Disparities Committee
- 61 Imaging Committee
- 62 Imaging-Medical Physics Joint Symposium
- 63 Lung Cancer General Meeting
- 64 Lung Core Committee
- 65 Medical Oncology Committee
- 66 Medical Physics Workshop
- 67 Ovarian Cancer Subcommittee
- 71 Particle Therapy Working Group
- 72 Pathology Committee
- 73 Patient Centered Outcomes Research (PCOR)
- 74 Pharmacy Subcommittee
- 75 Protocol Support Cmte (PSC)
- 76 PSC Educational Session - Roundtables
- 78 PSC Working Group Sessions
- 83 Radiation Oncology Committee
- 84 Rare Tumor Subcommittee
- 86 Sarcoma Working Group
- 88 Translational Science Committee
- 89 Translational Science Brain Cancer
- 90 Translational Science GU Cancer
- 91 Translational Science GYN
- 92 Translational Science Head & Neck Cancer
- 93 Translational Science Lung Cancer

INSTITUTIONAL ACCRUAL

- 95 Member Accrual

ACKNOWLEDGEMENTS

- 100 Commercial Supporters Acknowledgement
- 101 Sponsor/Exhibitor Acknowledgements
- 104 Ad Page - Eisai
- 105 Ad Page - Castle Biosciences
- 106 Future Meeting Dates and Locations
After all this time apart, we excitedly welcome our research community to the hybrid July 2022 NRG Oncology Semiannual Meeting in Chicago!

NRG Oncology’s semiannual meetings seek to promote collaboration among our researchers and to provide first-rate educational sessions exploring recent advances in clinical and basic cancer research and exciting new directions of inquiry. We encourage our members to become actively engaged in the exchange of ideas and information in the establishment of criteria for rigorous review of our science, and in the educational opportunities including specific workshops convened by NRG Oncology experts.

Meeting highlights include:

Join us for the Summer 2022 Hybrid Educational Symposium, “Targeted Therapies – Focus on the Future”, Thursday, July 21, 2022 from 8:00 AM to 12:00 PM CT. Targeted audiences are members and non-members of the NRG Oncology research teams to include: Gynecologic Oncologists, Medical Oncologists, Radiation Oncologists, Pathologists, Patient Advocates and others engaged in oncology research and/or clinical practice; Oncology Nurses, Nurse-practitioners, Physician Assistants, and other interested Allied Health professionals.

The NRG Publications Committee will be hosting the Scientific Session recapping recent keynote publications for studies such as NRG-BR002, NRG-HN002, GOG0-0259, RTOG-9402, RTOG-1010, and a presentation on prostate cancer therapy personalization through multi-modal deep learning.

During the General Session, you will hear updates on the various areas of our organization from NRG leadership including membership news and top accruing members, NCORP highlights, updates from our Statistics and Data Management Centers and Biobanks, and more.

Continued on next page
The NRG NCORP Town Hall is a hybrid session hosted by the NRG National Community Oncology Research Program (NCORP) and features a presentation on the NRG-CC008 NCORP Community Experience and Best Practices by Kari Ring, MD, of the University of Virginia Cancer Center. There will also be updates from NRG’s NCORP Principal Investigators, and presentations on NCI NCORP and NCI’s Cancer Care Delivery Research (CCDR).

The NRG Oncology Communications Committee is pleased to announce our Social Media Workshop as part of #NRG2022. The workshop is being held as a hybrid session and is scheduled for Friday, July 22, from 8:30 to 9:30 AM CT. Kristin Higgins, MD (Winship Cancer Institute of Emory University), a member of the NRG Oncology Communications Committee, is the workshop chair and will be discussing social media tools to enhance clinical trial accrual. The session speakers include Dan Golden, MD, MHPE, a radiation oncologist from the University of Chicago and Montessa Lee, a National Board-Certified Teacher and patient advocate for lung cancer awareness.

We look forward to engaging with and learning from our community with all the great discussions that come from the NRG Meeting this time. As always, we look forward to receiving your feedback and input into how to continue to improve your NRG Meeting experience.

Welcome to Chicago!

#NRG2022
NRG Oncology seeks to improve the lives of cancer patients by conducting practice-changing multi-institutional clinical and translational research with emphases on gender-specific malignancies including gynecologic, breast, and prostate cancers and on localized or locally advanced cancers of all types.

For the Educational Objectives, we list the following:

- Inform the participants of the current state of clinical and basic oncologic research, particularly, but not exclusively as it relates to clinical trials.

- Provide participants with peer review critiques of progress (or lack of it) with the objective of self-improvement.

- Provide an opportunity to learn research administration and financial management in a cooperative group setting.

- Provide a forum for experts from diverse fields to improve research practices and patient management.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Joint Providership of The GOG Foundation, Inc. and NRG Oncology.

The GOG Foundation, Inc. is accredited by the ACCME to provide Continuing Education for physicians.

AMA PRA Category 1 Credits™
The GOG Foundation, Inc. designates this live activity for a maximum of 30.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The GOG Foundation Inc. Continuing Education (CME) Program Mission Statement
The purpose of The GOG Foundation, Inc. CE program is to provide and promote an infrastructure dedicated to enhancing the knowledge base of meeting participants and guests centered on the development, execution, analysis and application of GOG-supported clinical trials. To that end, the CME Program engages in these discussions member researchers and invited clinicians committed to reducing the risk and improving outcomes for women at risk for or afflicted with a gynecologic malignancy.

Disclosure Declaration
In compliance with ACCME regulations, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation. Please see the complete disclosure list included with this program.

How do I collect CME/CEU Certificates?

Surveys/Evaluations

In-Person Attendees: After you attend your session(s), Go on the Meeting App and click the "Take Survey" icon located at the bottom of the home page of the app OR Surveys can also be found in your personal profile located on bottom toolbar.

Virtual Attendees: After you attend your session(s), click the "Take Survey" icon located at the bottom of the Attendee Hub Home Page OR For some sessions you may see the "Survey" Icon located on the right side of the Attendee Hub

These links will direct you to all the evaluations/surveys available to you for completion.

CMEs/CEUs Certificates
Upon completion of your evaluations/surveys, certificates will be sent to the email you used to register.

If you have issues accessing your certificate or questions about CME/CEUs, please contact: cmeinfo@gog.org.

For questions or comments about this CME activity, please contact:
Michelle N. Small, MHA
Dir, Education Programs/CME Compliance at smallm@nrgoncology.org
CME Credit Listing

The following sessions/workshops have been approved to receive CME credits for the hybrid meeting July 18-26, 2022

Maximum credits is 30.5 AMA PRA category one credits™

<table>
<thead>
<tr>
<th>Session TITLE</th>
<th>MON 7/18</th>
<th>Tues 7/19</th>
<th>WED 7/20</th>
<th>THURS 7/21</th>
<th>FRI 7/22</th>
<th>SAT 7/23</th>
<th>MON 7/25</th>
<th>TUE 7/26</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symposium- Targeted Therapies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.75</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.0</td>
</tr>
<tr>
<td>Canadian Members Subcommittee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.0</td>
</tr>
<tr>
<td>Cancer Prevention and Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.0</td>
</tr>
<tr>
<td>Cancer Care Delivery Research (CCDR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.0</td>
</tr>
<tr>
<td>Cervix Workshop</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.0</td>
</tr>
<tr>
<td>Developmental Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.0</td>
</tr>
<tr>
<td>Developmental Therapeutics –Radiation (DTRT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Genitourinary Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Gynecologic Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Head and Neck</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Lung Cancer NRG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Medical Oncology Committee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.0</td>
</tr>
<tr>
<td>NCORP Town Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Ovarian Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.5</td>
</tr>
<tr>
<td>Particle Therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Pathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.0</td>
</tr>
<tr>
<td>Patient Centered Outcomes (PCOR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Pharmacy Subcommittee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Rare Tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.0</td>
</tr>
<tr>
<td>Scientific Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Social Media</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.0</td>
</tr>
<tr>
<td>Translational Science Gyn</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Translational Science</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.0</td>
</tr>
<tr>
<td>PSC CTR/CRA Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.5</td>
</tr>
<tr>
<td>PSC CTR/CRA Round Tables</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.25</td>
</tr>
</tbody>
</table>
NRG ONCOLOGY
2022 SUMMER MEETING

Stay up to date:

@NRGOnc
#NRG2022

@nrgoncology

@NRGOnc

@nrgoncology

Network Login: nrgmeeting
Passcode: n1r2g345
Go to Apple store or Google Store
Download the CVENT App
Select CVENT EVENTS
Search for Event = NRG
Select:
NRG Oncology Summer Meeting
Event ID = NRG ONC22
(Please note there is a space after NRG)

Once you are in the NRG Oncology Summer Meeting, enter your first name, last name, and email.

You'll receive a verification code to enter on the screen. Tap the arrow.

Opt in to receive push notifications so you don’t miss any important information!
WELCOME TO HYATT REGENCY CHICAGO. Meeting rooms, ballrooms, restaurants and guest amenities are listed in alphabetical order and color coded by floor. For help, dial Guest Services at Extension 52.

ACAPULCO (International and City Suites)
West Tower, Ballroom Level

ADAMS (Founders Suites)
West Tower, Third Floor

ADAMS FOYER
West Tower, Third Floor

AMERICAN CRAFT KITCHEN & BAR
East Tower, Lobby Level

ATLANTA (International and City Suites)
West Tower, Ballroom Level

BELL DESK
East Tower, Skyway Level

BIG BAR
East Tower, Skyway Level

BURNHAM (Founders Suites)
West Tower, Third Floor

BUSINESS CENTER, PACKAGE ROOM
West Tower, Exhibit Level

COLUMBIAN (Landmark Suites)
West Tower, Concourse Level

COMISKEY (Landmark Suites)
West Tower, Concourse Level

CONCIERGE
East Tower, Lobby Level

CRYSTAL BALLROOM
West Tower, Lobby Level

DASHER (Founders Suites)
West Tower, Third Floor

DUSABLE (Founders Suites)
West Tower, Third Floor

EAST TOWER MAIN ENTRANCE
East Tower, Lobby Level

EAST TOWER VALET
East Tower, Ballroom Level

FIELD (Founders Suites)
West Tower, Third Floor

FITNESS CENTER
West Tower, Skyway Level

FRONT DESK
East Tower, Skyway Level

THE GALLERY COLLECTION
West Tower, Skyway Level

GIFT SHOP
East Tower, Concourse Level

GOLD COAST (Landmark Suites)
West Tower, Concourse Level

GRAND BALLROOM
East Tower, Ballroom Level

GRAND HALL (ROOMS G-N)
East Tower, Ballroom Level

GRAND SUITES
East Tower, Ballroom Level

HAYMARKET (Landmark Suites)
West Tower, Concourse Level

HERTZ
East Tower, Skyway Level

HONG KONG (International and City Suites)
West Tower, Ballroom Level

HORNER (Founders Suites)
West Tower, Third Floor

THE LIVING ROOM
West Tower, Skyway Level

MARKET CHICAGO
East Tower, Lobby Level

McCORMICK (Founders Suites)
West Tower, Third Floor

MICHIGAN (Lakeshore Meeting Rooms)
East Tower, Concourse Level

MONROE (Lakeshore Meeting Rooms)
East Tower, Concourse Level

NEW ORLEANS (International and City Suites)
West Tower, Ballroom Level

OGDEN (Founders Suites)
West Tower, Third Floor

PICASSO (Landmark Suites)
West Tower, Concourse Level

PLAZA BALLROOM
East Tower, Lobby Level

RANDOLPH (Lakeshore Meeting Rooms)
East Tower, Concourse Level

REGENCY BALLROOM
East Tower, Ballroom Level

RIVERSIDE CENTER
East Tower, Exhibit Level

ROOSEVELT (Lakeshore Meeting Rooms)
East Tower, Concourse Level

SAN FRANCISCO (International and City Suites)
West Tower, Ballroom Level

SKYWAY MEETING ROOMS
East Tower, Skyway Level

SOLDIER FIELD (Landmark Suites)
West Tower, Concourse Level

STETSON CONFERENCE CENTER
West Tower, Exhibit Level

STETSONS MODERN STEAK + SUSHI
East Tower, Lobby Level

TORONTO (International and City Suites)
West Tower, Ballroom Level

WATER TOWER (Landmark Suites)
West Tower, Concourse Level

WEST TOWER VALET
West Tower, Exhibit Level

WEST TOWER VALET
West Tower, Ballroom Level

WEST TOWER VALET
West Tower, Exhibit Level

WEST TOWER VALET
West Tower, Ballroom Level

WEST TOWER VALET
West Tower, Exhibit Level

WRIGHT (Founders Suites)
West Tower, Third Floor

WRIGLEY (Landmark Suites)
West Tower, Concourse Level

CONCOURSE LEVEL
Bronze Level

LAKESHORE MEETING ROOMS

BALLROOM LEVEL
Gold Level

SKYWAY MEETING ROOMS

SKYWAY LEVEL
Blue Level

FINDERS SUITES

WEST TOWER
ELEVATORS, ELEVATORS AND RESTROOMS are indicated on each floor. Elevators are conveniently located throughout the hotel for guests with disabilities or where no escalator is present.

CROSSING BETWEEN TOWERS: Cross between towers via the Skybridge or the Concourse. You may also cross from the lobby level via the crosswalk on Stetson Drive.
# NRG Oncology Semiannual Meeting
## Final Schedule
**Hyatt Regency Chicago**  
**Chicago, IL**  
**July 18 – 26, 2022 (All Sessions Central Time)**

### Monday, July 18, 2022
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 am – 12:00 pm</td>
<td>Translational Science Lung Subcommittee</td>
<td>Virtual</td>
</tr>
<tr>
<td>10:00 am – 12:00 pm</td>
<td>Medical Oncology Committee</td>
<td>Virtual</td>
</tr>
<tr>
<td>12:00 pm – 1:00 pm</td>
<td>NRG QA Subcommittee <em>(Closed)</em></td>
<td>Virtual</td>
</tr>
<tr>
<td>12:30 pm – 1:30 pm</td>
<td>Imaging Committee</td>
<td>Virtual</td>
</tr>
<tr>
<td>1:30 pm – 2:30 pm</td>
<td>Joint Imaging and Medical Physics Seminar “TBD”</td>
<td>Virtual</td>
</tr>
<tr>
<td>2:30 pm – 4:00 pm</td>
<td>Medical Physics Subcommittee Meeting</td>
<td>Virtual</td>
</tr>
<tr>
<td>3:30 pm – 5:00 pm</td>
<td>Radiation-Developmental Therapeutics Subcommittee</td>
<td>Virtual</td>
</tr>
</tbody>
</table>

### Tuesday, July 19, 2022
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 pm – 2:00 pm</td>
<td>Pharmacy Subcommittee</td>
<td>Virtual</td>
</tr>
</tbody>
</table>
**NRG ONCOLOGY SEMIANNUAL MEETING**

**FINAL SCHEDULE**

Hyatt Regency Chicago
Chicago, IL

July 18 – 26, 2022 (All Sessions Central Time)

### Thursday, July 21, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am – 8:00 am</td>
<td>Symposium Breakfast</td>
<td>Grand AB/Ballroom Level/East Tower</td>
</tr>
<tr>
<td>7:00 am – 8:00 am</td>
<td>PSC Continuing Education Breakfast</td>
<td>Grand EF/Ballroom/East</td>
</tr>
<tr>
<td>7:00 am – 6:00 pm</td>
<td>Registration/Information Desk</td>
<td>Grand Registration Desk/East</td>
</tr>
<tr>
<td>2:00 pm – 4:00 pm</td>
<td>General Coffee Break</td>
<td>Grand Foyer/Ballroom/East</td>
</tr>
<tr>
<td>3:00 pm – 5:00 pm</td>
<td>Exhibit Setup</td>
<td>Grand MN/Ballroom/East</td>
</tr>
<tr>
<td>8:00 am – 11:45 am</td>
<td>PSC Continuing Educational Session</td>
<td>Hybrid/Grand EF</td>
</tr>
<tr>
<td>8:00 am – 12:00 pm</td>
<td>Summer Symposium - “Targeted Therapies – Focus on the Future”</td>
<td>Hybrid/Grand AB</td>
</tr>
<tr>
<td>9:00 am – 10:00 am</td>
<td>International Members Meeting</td>
<td>Michigan 3/Concourse/East</td>
</tr>
<tr>
<td>9:00 am – 12:00 pm</td>
<td>DMC Panel A (Closed)</td>
<td>Virtual/Wrigley/Concourse/West</td>
</tr>
<tr>
<td>10:00 am – 12:00 pm</td>
<td>Cancer Care Delivery Research Committee</td>
<td>Plaza/Lobby/East</td>
</tr>
<tr>
<td>11:00 am – 12:00 pm</td>
<td>Canadian Members Meeting</td>
<td>Michigan 3/Concourse/East</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Publications Committee (Closed)</td>
<td>Randolph 2/Concourse/East</td>
</tr>
<tr>
<td>12:00 pm – 2:00 pm</td>
<td>Cancer Prevention and Control Committee</td>
<td>Plaza/Lobby/East</td>
</tr>
<tr>
<td>12:05 pm – 1:00 pm</td>
<td>PSC Luncheon Speaker</td>
<td>Hybrid/Grand EF</td>
</tr>
<tr>
<td>12:30 pm – 2:30 pm</td>
<td>Developmental Therapeutics Committee</td>
<td>Hybrid/Grand AB</td>
</tr>
<tr>
<td>1:00 pm – 2:30 pm</td>
<td>Membership Meeting (Closed)</td>
<td>Michigan 3/Concourse/East</td>
</tr>
<tr>
<td>1:00 pm – 4:00 pm</td>
<td>DMC Panel B (Closed)</td>
<td>Virtual/Wrigley/Concourse/West</td>
</tr>
<tr>
<td>1:30 pm – 4:45 pm</td>
<td>PSC Continuing Education Session - Roundtables</td>
<td>Crystal BC/Lobby/West</td>
</tr>
<tr>
<td>2:00 pm – 3:30 pm</td>
<td>PCOR Committee</td>
<td>Hybrid/Grand EF</td>
</tr>
<tr>
<td>2:00 pm – 4:00 pm</td>
<td>Rare Tumor Subcommittee</td>
<td>Grand G-I/Ballroom/East</td>
</tr>
<tr>
<td>3:00 pm – 5:00 pm</td>
<td>Imaging &amp; Radiation Oncology Core (IROC) QA Centers Meeting (Closed)</td>
<td>Michigan 2/Concourse/East</td>
</tr>
<tr>
<td>3:00 pm – 5:00 pm</td>
<td>NRG-Harvard-Ohio State-Case Western R01 Grant Meeting (Closed)</td>
<td>Randolph 2/Concourse/East</td>
</tr>
<tr>
<td>3:30 pm – 4:30 pm</td>
<td>Early Career New Investigator Educational Session</td>
<td>Plaza/Lobby/East</td>
</tr>
<tr>
<td>4:00 pm – 5:00 pm</td>
<td>DMC Panel C (Closed)</td>
<td>Virtual/Wrigley/Concourse/West</td>
</tr>
<tr>
<td>4:00 pm – 5:30 pm</td>
<td>Patient Advocates Meeting</td>
<td>Randolph 1/Concourse/East</td>
</tr>
<tr>
<td>4:00 pm – 6:00 pm</td>
<td>Translational Science Workshop</td>
<td>Hybrid/Grand AB</td>
</tr>
<tr>
<td>4:30 pm – 5:30 pm</td>
<td>Early Career New Investigator Networking Session</td>
<td>Plaza/Lobby/East</td>
</tr>
<tr>
<td>5:00 pm – 6:30 pm</td>
<td>PSC Education &amp; Training Working Group (Closed)</td>
<td>Skyway 260/Skyway/East</td>
</tr>
<tr>
<td>5:00 pm – 6:30 pm</td>
<td>PSC Mentorship Working Group (Closed)</td>
<td>Randolph 2/Concourse/East</td>
</tr>
<tr>
<td>5:00 pm – 6:30 pm</td>
<td>PSC Protocol Review Working Group (Closed)</td>
<td>Michigan 2/Concourse/East</td>
</tr>
<tr>
<td>5:00 pm – 6:30 pm</td>
<td>PSC Quality Control Working Group (Closed)</td>
<td>Skyway 272/Skyway/East</td>
</tr>
<tr>
<td>5:00 pm – 7:00 pm</td>
<td>Committee Chairs Dinner (Closed)</td>
<td>Michigan 1/Concourse/East</td>
</tr>
</tbody>
</table>

Revised 7/18/2022

All Sessions Central Time
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 pm – 8:00 pm</td>
<td>NCORP Concept Review <em>(Invitation Only)</em></td>
<td>Roosevelt 3AB/Concourse/East</td>
</tr>
<tr>
<td>7:00 pm – 9:00 pm</td>
<td>Ancillary Projects Committee <em>(Closed)</em></td>
<td>Michigan 2/Concourse/East</td>
</tr>
</tbody>
</table>
# NRG Oncology Semiannual Meeting
## Final Schedule
### Hyatt Regency Chicago, Chicago, IL
July 18 – 26, 2022 (All Sessions Central Time)

### Friday, July 22, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am – 8:30 am</td>
<td>Continental Breakfast</td>
<td>Grand MN/Ballroom/East</td>
</tr>
<tr>
<td>7:00 am – 5:00 pm</td>
<td>Exhibits</td>
<td>Grand MN/Ballroom/East</td>
</tr>
<tr>
<td>7:00 am – 5:30 pm</td>
<td>Registration/Information Desk</td>
<td>Grand Registration Desk/East</td>
</tr>
<tr>
<td>9:00 am – 10:00 am</td>
<td>Brain Tumor Core Committee (Closed)</td>
<td>Grand KL/Ballroom/East</td>
</tr>
<tr>
<td>10:00 am – 11:30 am</td>
<td>NCORP Townhall</td>
<td>Hybrid/Grand AB</td>
</tr>
<tr>
<td>10:00 am – 12:00 pm</td>
<td>Head &amp; Neck Core Committee (Closed)</td>
<td>Michigan 1/Concourse/East</td>
</tr>
<tr>
<td>10:00 am – 12:00 pm</td>
<td>Sarcoma Working Group</td>
<td>Gold Coast/Concourse/West</td>
</tr>
<tr>
<td>10:00 am – 12:00 pm</td>
<td>Uterine Corpus Cancer Subcommittee</td>
<td>Grand CD/Ballroom/East</td>
</tr>
<tr>
<td>10:15 am – 11:45 am</td>
<td>Neurosurgical Subcommittee</td>
<td>Grand KL/Ballroom/East</td>
</tr>
<tr>
<td>12:00 pm – 1:00 pm</td>
<td>General Session</td>
<td>Hybrid/Grand EF</td>
</tr>
<tr>
<td>1:15 pm – 2:30 pm</td>
<td>FORTE Workshop</td>
<td>Hybrid/Grand EF</td>
</tr>
<tr>
<td>1:15 pm – 2:45 pm</td>
<td>Brain Tumor Committee General Session</td>
<td>Hybrid/Grand AB</td>
</tr>
<tr>
<td>1:15 pm – 2:45 pm</td>
<td>Translational Science Breast Cancer Subcommittee (Closed)</td>
<td>Grand G-I/Ballroom/East</td>
</tr>
<tr>
<td>1:15 pm – 3:15 pm</td>
<td>GU Cancer Core Committee (Closed)</td>
<td>Grand KL/Ballroom/East</td>
</tr>
<tr>
<td>1:15 pm – 3:15 pm</td>
<td>Lung Cancer Core Committee (Closed)</td>
<td>Randolph 1AB/Concourse/East</td>
</tr>
<tr>
<td>1:15 pm – 3:45 pm</td>
<td>Ovarian Cancer Subcommittee</td>
<td>Grand CD/Ballroom/East</td>
</tr>
<tr>
<td>2:00 pm – 3:00 pm</td>
<td>Translational Science Head &amp; Neck</td>
<td>Grand J/Ballroom/East</td>
</tr>
<tr>
<td>3:00 pm – 4:30 pm</td>
<td>Scientific Session</td>
<td>Hybrid/Grand EF</td>
</tr>
<tr>
<td>4:30 pm – 5:30 pm</td>
<td>Radiation Oncology GYN Subcommittee</td>
<td>Gold Coast/Concourse/West</td>
</tr>
<tr>
<td>4:30 pm – 6:00 pm</td>
<td>Translational Science GU Subcommittee</td>
<td>Grand G-I/Ballroom/East</td>
</tr>
<tr>
<td>4:30 pm – 6:00 pm</td>
<td>Translational Science GYN Subcommittee</td>
<td>Virtual</td>
</tr>
<tr>
<td>4:30 pm – 6:30 pm</td>
<td>Translational Science Brain Cancer Subcommittee</td>
<td>Grand J/Ballroom/East</td>
</tr>
<tr>
<td>4:45 pm – 6:15 pm</td>
<td>Head &amp; Neck General Committee</td>
<td>Hybrid/Grand AB</td>
</tr>
<tr>
<td>4:45 pm – 6:45 pm</td>
<td>Breast Cancer Core Committee (Closed)</td>
<td>Grand KL/Ballroom/East</td>
</tr>
</tbody>
</table>

Revised 7/18/2022

All Sessions Central Time
### Friday, July 22, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 pm – 6:00 pm</td>
<td>FORTE Reception</td>
<td>Plaza/Lobby/East</td>
</tr>
<tr>
<td>5:00 pm – 7:00 pm</td>
<td>Korean Gynecologic Oncology Group</td>
<td>Roosevelt 3AB/Concourse/East</td>
</tr>
<tr>
<td>6:00 pm – 8:00 pm</td>
<td>NRG Oncology Welcome Reception</td>
<td>Crystal Ballroom/Lobby/West</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td><strong>Saturday, July 23, 2022</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:30 am – 8:30 am</td>
<td>Continental Breakfast</td>
<td>Grand MN/Ballroom/East</td>
</tr>
<tr>
<td>7:00 am – 12:30 pm</td>
<td>Registration/Information Desk</td>
<td>Grand Registration Desk/East</td>
</tr>
<tr>
<td>7:00 am – 1:00 pm</td>
<td>Exhibits</td>
<td>Grand MN/Ballroom/East</td>
</tr>
<tr>
<td>6:00 am – 8:00 am</td>
<td>Luminal B Early Breast Cancer Design Meeting <em>(Closed)</em></td>
<td>Skyway 272/Skyway/East</td>
</tr>
<tr>
<td>6:45 am – 8:15 am</td>
<td>Particle Working Group</td>
<td>Grand KL/Ballroom/East</td>
</tr>
<tr>
<td>7:00 am – 8:30 am</td>
<td>Protocol Operations Management Committee <em>(Closed)</em></td>
<td>Skyway 260/Skyway/East</td>
</tr>
<tr>
<td>7:00 am – 9:30 am</td>
<td>Protocol Support Committee Executive Session <em>(Closed)</em></td>
<td>Randolph 1AB/Concourse/East</td>
</tr>
<tr>
<td>7:30 am – 9:00 am</td>
<td>Genitourinary Cancer General Committee</td>
<td>Hybrid/Grand EF</td>
</tr>
<tr>
<td>7:45 am – 9:30 am</td>
<td>Gynecologic Cancer Committee</td>
<td>Hybrid/Grand AB</td>
</tr>
<tr>
<td>9:15 am – 10:30 am</td>
<td>Gastrointestinal Colorectal Cancer Core Committee <em>(Closed)</em></td>
<td>Grand J/Ballroom/East</td>
</tr>
<tr>
<td>9:15 am – 11:00 am</td>
<td>Lung Cancer General Committee</td>
<td>Hybrid/Grand EF</td>
</tr>
<tr>
<td>10:45 am – 12:15 pm</td>
<td>Gastrointestinal Non-Colorectal Cancer Committee <em>(Closed)</em></td>
<td>Grand J/Ballroom/East</td>
</tr>
<tr>
<td>11:30 am – 1:30 pm</td>
<td>Breast Cancer Committee</td>
<td>Hybrid/Grand EF</td>
</tr>
<tr>
<td>12:30 pm – 2:00 pm</td>
<td>Gastrointestinal Cancer General Committee</td>
<td>Hybrid/Grand AB</td>
</tr>
<tr>
<td><strong>Monday, July 25, 2022</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 am – 12:45 pm</td>
<td>Health Disparities Committee Meeting</td>
<td>Virtual</td>
</tr>
<tr>
<td>1:00 pm – 3:00 pm</td>
<td>Pathology Committee</td>
<td>Virtual</td>
</tr>
</tbody>
</table>
Program Description

This Summer 2022 Hybrid Educational Symposium is being held in-person and virtually with noted Oncologists and Scientists serving as speakers and moderators.

The targeted audiences are members and non-members of the NRG research teams to include: Gynecologic Oncologists, Medical Oncologists, Radiation Oncologists, Pathologists, Patient Advocates and others engaged in oncology research and/or clinical practice; Oncology Nurses, Nurse-practitioners, Physician Assistants, and other interested Allied Health professionals.

The speakers will focus their presentations on:

- Appropriate settings to utilize currently available targeted therapies
- Current clinical trials of novel targeted therapies
- Promising future approaches in targeted therapies.

Learning Objectives

Following this activity, participants will be better able to:

- Recognize appropriate settings to utilize currently available targeted therapies
- Outline future clinical trial opportunities for patients
- Distinguish current and promising future approaches to targeted therapies
- Manage toxicity related to targeted therapies
Summer 2022 Symposium - “Targeted Therapies – Focus on the Future”
Thurs, July 21, 2022 – 8 am to 12 pm – CDT - NRG Oncology Summer 2022 Mtg- Chicago, Illinois – (In-person/Virtual)

Presentation Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>Welcome/Opening Remarks</td>
<td>Katherine Fuh, MD, PHD</td>
</tr>
<tr>
<td>8:05 am</td>
<td>Session 1 – Focus on other Solid Tumors</td>
<td>Moderators: Rebecca Arend, MD and Britt Erickson, MD</td>
</tr>
<tr>
<td>8:05-8:25</td>
<td>Lessons from Lung Cancer</td>
<td>Marina Garassino, MD</td>
</tr>
<tr>
<td>8:25-8:45</td>
<td>Targeted Therapies with Radiation in Locally Advanced Cervical Cancer and Solid Tumors</td>
<td>Jyoti Mayadev, MD</td>
</tr>
<tr>
<td>8:45-9:05</td>
<td>HER2 Targeting Agents</td>
<td>Ecaterina Dumbrava, MD</td>
</tr>
<tr>
<td>9:05-9:15</td>
<td>Panel Q &amp; A</td>
<td>Panel</td>
</tr>
<tr>
<td>9:15-9:25</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>9:25</td>
<td>Session 2 – Focus on the Future</td>
<td>Moderators: Deb Richardson, MD and Haider Mahdi, MD</td>
</tr>
<tr>
<td>9:25-9:45</td>
<td>Targeting the DNA Damage Response and Repair</td>
<td>Yvette Drew, MD, PhD</td>
</tr>
<tr>
<td>9:45-10:05</td>
<td>Focus on Eye Toxicities</td>
<td>Gottfried Konecny, MD, PhD</td>
</tr>
<tr>
<td>10:05-10:25</td>
<td>Bispecifics/ Antibody Drug Conjugates</td>
<td>Yeku Oladapo, MD, PhD</td>
</tr>
<tr>
<td>10:25-10:35</td>
<td>Panel Q &amp; A</td>
<td>Panel</td>
</tr>
<tr>
<td>10:35-10:45</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Session 3 – Focus on the Patient</td>
<td>Moderators: Stephanie Blank, MD and Emma Barber, MD</td>
</tr>
<tr>
<td>10:45-11:05</td>
<td>Targeting Financial Toxicity</td>
<td>Emeline Aviki, MD</td>
</tr>
<tr>
<td>11:05-11:35</td>
<td>Targeting Skin Toxicity</td>
<td>Mario Lacouture, MD</td>
</tr>
<tr>
<td>11:35-11:45</td>
<td>NCI ComboMATCH</td>
<td>Roisin O’Cearbhaill, MD</td>
</tr>
<tr>
<td>11:45-11:55</td>
<td>Panel Q &amp; A</td>
<td>Panel</td>
</tr>
<tr>
<td>11:55-12:00</td>
<td>Closing Remarks</td>
<td>Roisin O’Cearbhaill, MD</td>
</tr>
</tbody>
</table>

Evaluation

Participants who complete the educational activity and evaluation will receive a certificate of credit.

Disclosure Declaration

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. All relevant financial relationships listed for these individuals have been mitigated to ensure a bias-free presentation. Please see the faculty disclosure list for detailed information.
PROTOCOL SUPPORT COMMITTEE
ROUND TABLE SESSIONS*

July 21, 2022
1:30-4:45 pm CDT
*In-person offering

Breast Cancer Trials
Colorectal Cancer Trials
GYN Cancer Trials
The FORTE Study
PRO Compliance
QA Program
Informed Consents
AE Reporting
CTSU
Best Practices

Please refer to the agenda on the #NRG2022 meeting website for the complete schedule of topics.
Speakers

NRG Overview
Quynh-Thu Le, MD
Stanford University
An NRG Oncology Group Chair

Just Ask: Increasing Diverse Participation in Clinical Trials
Nadine Barrett, PhD
Director, Center for Equity Research
Duke Clinical & Translational Science Institute

NRG Veterans Affairs/Military Treatment Facility (VA-MTF) Subcommittee Overview
Vlad Sandulache, MD, PhD
Baylor College of Medicine
NRG VA-MTF Subcommittee Chair

NIH/DOD Grant Opportunities for NRG Trials
Victoria Bae-Jump, MD, PhD
Professor of Gynecologic Oncology
UNC Linebecker Comprehensive Cancer Center

#NRG2022
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 3:30 pm – 3:32 pm | Welcome Remarks  
An NRG Oncology Early Career New Investigator Chair |
| 3:32 pm – 3:40 pm | NRG Overview  
Quynh-Thu Le, MD |
| 3:40 pm – 3:55 pm | Just Ask: Increasing Diverse Participation in Clinical Trials  
Nadine Barrett, PhD |
| 3:55 pm – 4:05 pm | NRG Veterans Affairs/Military Treatment Facility (VA-MTF) Subcommittee Overview  
Vlad Sandulache, MD, PhD |
| 4:05 pm – 4:20 pm | NIH/DOD Grant Opportunities for NRG Trials  
Victoria Bae-Jump, MD, PhD |
| 4:20 pm – 4:28 pm | Panel for Questions & Answers and |
| 4:28 pm – 4:30 pm | Closing Remarks  
An NRG Oncology Session Chair |
Translational Science Workshop

Thursday, July 21, 2022
4:00-6:00pm CT

Hybrid Session

#NRG2022

Speakers

"Clinical Utility of ctDNA for Breast Cancer: The Breast is Yet to Come"

Ben Ho Park, MD, PhD
Vanderbilt University Medical Center
@benhopark

“Rethinking Breast Cancer Risk Modeling with AI”

Prof. Regina Barzilay
MIT Computer Science & Artificial Intelligence Lab
@BarzilayRegina

“Influence of African Ancestry on Tumor Biology”

Melissa Boneta Davis, PhD
Weill Cornell Medicine

Session Chairs

Michael Birrer, MD, PhD
University of Arkansas for Medical Sciences
NRG Oncology Meeting - July 2022

Adam Dicker, MD, PhD
Sidney Kimmel Cancer Center at Thomas Jefferson University
@APDicker

Vered Stearns, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
@VeredStearns
Social Media Workshop

Friday, July 22, 2022
8:30-9:30am CT

Session Chair
Kristin A. Higgins, MD
Winship Cancer Institute of Emory University
@KHigginsMD
Social Media Tools to Enhance Clinical Trial Accrual

Speakers
Daniel W. Golden, MD, MHPE
University of Chicago
@d_golden
Using Social Media to Educate the Next Generation of Oncologists

Montessa Lee
Small Cell Lung Cancer Patient Advocate
@MontessaLee
The Patient's Point of View

#NRG2022
NRG Oncology Meeting - July 2022
Date:          Friday, July 22, 2022  
Start and End Time:  8:30 am – 9:30 am CDT  
Chair:          Kristin Higgins, MD  

Learning Objectives:  
Following this activity, participants will be better able to:  

1. To understand the paradigm shifts in oncology using social media  
2. To understand the importance of patient advocacy using social media  
3. To gain knowledge how social media helps with clinical trial recruitment  

WORKSHOP AGENDA  
"Welcome and Introductions"  
Kristin A. Higgins, MD  
Winship Cancer Institute of Emory University  

"Using Social Media to Educate the Next Generation of Oncologists"  
Daniel W. Golden, MD, MHPE  
University of Chicago  

"Social Media Tools to Enhance Clinical Trial Accrual"  
Kristin A. Higgins, MD  
Winship Cancer Institute of Emory University  

"The Patient's Point of View"  
Montessa Lee  
Small Cell Lung Cancer Patient Advocate  

Panel Discussion: Drs. Higgins and Golden, and Ms. Lee  

QUESTIONS / DISCUSSION  
Social media is increasingly used by physicians and patients. Over the past few years, many paradigm shifts in medicine have been facilitated via social media discussions. Physicians will benefit from learning how to use these tools to advance medicine. This panel will discuss how social media helps with clinical trial recruitment from both the physician and patient perspective.
**NCORP Town Hall**

**Friday, July 22, 2022**

**10:00-11:30am CT**

**Hybrid Session**

#NRG2022

---

**Speakers**

**Kari Ring, MD**
University of Virginia Cancer Center

"NRG-CC008: NCORP Community Site Experience and Best Practices"

**Sandra Russo, MD**
Community Oncology and Prevention Trials Research Group, DCP

"NCI NCORP Update"

**Kathleen Castro, RN, MS**
Nurse Consultant, Office of the Associate Director of the Healthcare Delivery Research Program

"NCI CCDR Update"

---

**NCORP PIs**

**Deborah W. Bruner, PhD, RN**
Winship Cancer Institute of Emory University

**Joan Walker, MD**
University of Oklahoma Stephenson Cancer Center
NCORP TOWN HALL AGENDA
Friday, July 22, 2022
10:00 – 11:30am CST

Learning Objectives
Following this activity, participants will be better able to:
1. Discuss proposed and ongoing NRG NCORP research trials.
2. Apply procedures required to implement a protocol within NCORP.
3. Learn about opportunities in CCDR and CPC clinical trials.

<table>
<thead>
<tr>
<th>Welcome</th>
<th>Deborah Bruner, PhD, RN, NRG NCORP PI</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG NCORP Updates/Announcements</td>
<td></td>
</tr>
<tr>
<td>PRO Compliance Recognition</td>
<td></td>
</tr>
<tr>
<td>NRG-CC008: NCORP community site experience and best practices</td>
<td>Kari Ring, MD, University of Virginia Cancer Center</td>
</tr>
<tr>
<td>Q&amp;A – Open Discussion</td>
<td></td>
</tr>
<tr>
<td>Introduction of NCI speakers</td>
<td>Deborah Bruner, PhD, RN, NRG NCORP PI</td>
</tr>
<tr>
<td>NCI NCORP Update</td>
<td>Sandra Russo, MD, Community Oncology and Prevention Trials Research Group, DCP</td>
</tr>
<tr>
<td>NCI CCDR Update</td>
<td>Kathleen Castro, RN, MS, Nurse Consultant, Office of the Associate Director of the Healthcare Delivery Research Program</td>
</tr>
<tr>
<td>Q&amp;A – Open Discussion</td>
<td></td>
</tr>
<tr>
<td>Closing Remarks</td>
<td>Deborah Bruner/Joan Walker</td>
</tr>
</tbody>
</table>
NRG CC005
FORTE Workshop

Friday, July 22, 2022
1:15-2:30pm CT

Hybrid Session

#NRG2022
NRG FORTE Workshop Agenda

Date: July 22, 2022
Start and End Time: 1:15-2:30pm

Chair: Robert Schoen, MD, MPH
Co-Chair: Jeffrey Dueker, MD, MPH

WORKSHOP AGENDA

A. Welcome
B. PART I
   a. FORTE is a National Priority
   b. How to approach GI docs about FORTE?
   c. How can NRG help you start FORTE at your site?
      • GI Contacts
      • Network application
      • Natural Language Processing (Pieces)
      • Incentive funding
C. Question and Answer
D. Part II
   a. How does FORTE operate at Metro-MN Community Oncology Research Consortium? (Virtual)
   b. Site Materials for Patient Recruitment;
   c. Communications and Social Media
   d. Data management
E. Question and Answer
F. Call to Action
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: 2nd long-term results of NRG/RTOG 9402 - reporting with a EORTC Study

Andrew B. Lassman, MD

Effects of the WRITE symptoms interventions on symptoms and quality of life among patients with recurrent ovarian cancers: an NRG Oncology/GOG Study (GOG-0259)

Heidi S. Donovan, PhD, RN

Prostate cancer therapy personalization via multi-modal deep learning

Osama Mohamad, MD, PhD

NRG-BR002: A phase IIIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) &/or surgical resection (SR) for newly oligometastatic breast cancer

Steven J. Chmura, MD

Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002

Sue S. Yom, MD, PhD

Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010

Theodore S. Hong, MD
NRG Scientific Session
NRG Oncology Research Review

Date: Friday, July 22, 2022
Start and End Time: 3:00 pm - 4:30 pm Central Time
Publications Chair-Moderator: Krishnansu S Tewari, MD
Publications Deputy Chair: Harry D Bear, MD, PhD
Publications Vice Chairs: Elizabeth M. Gore, MD and Thomas B Julian, MD

Learning Objectives:
Following this activity, participants will be better able to:

1. (Lassman) Understand the long-term results of chemoradiotherapy for anaplastic oligodentroglioma.
2. (Chmura) Describe primary results for phase IIR/III trial of standard of care systemic therapy for newly oligometastatic breast cancer, with or without stereotactic body radiotherapy (SBRT) &/or surgical resection (SR).
3. (Donovan) Understand the quality of life among patients in recurrent ovarian cancers using WRITE symptoms interventions on symptoms.
4. (Mohamad) Investigate how prostate cancer treatment can be personalized using multi-modal deep learning.
5. (Yom) Describe the association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome.
6. (Hong) Explain the primary results of using Trastuzumab with trimodality treatment of patients with untreated HER2-overexpressing oesophageal adenocarcinoma.

WORKSHOP AGENDA

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 – 3:05 pm</td>
<td>Welcome</td>
<td>Krishnansu S Tewari, MD</td>
</tr>
<tr>
<td>3:05 – 3:15 pm</td>
<td>Phase III trial of chemoradiotherapy for anaplastic oligodentroglioma: 2nd long-term results of NRG/RTOG 9402 - reporting with a EORTC Study</td>
<td>Andrew B Lassman, MD</td>
</tr>
<tr>
<td>3:15 – 3:25 pm</td>
<td>NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) &amp;/or surgical resection (SR) for newly oligometastatic breast cancer</td>
<td>Steven J Chmura, MD</td>
</tr>
<tr>
<td>3:25 – 3:35 pm</td>
<td>Effects of the WRITE symptoms interventions on symptoms and quality of life among patients with recurrent ovarian cancers: an NRG Oncology/GOG Study (GOG-0259)</td>
<td>Heidi S Donovan, RN, PhD</td>
</tr>
<tr>
<td>3:35 – 3:45 pm</td>
<td>Prostate cancer therapy personalization via multi-modal deep learning</td>
<td>Osama Mohamad, MD</td>
</tr>
<tr>
<td>3:45 – 3:55 pm</td>
<td>Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.</td>
<td>Sue S Yom, MD</td>
</tr>
<tr>
<td>3:55 – 4:05 pm</td>
<td>Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010</td>
<td>Theodore S Hong, MD</td>
</tr>
<tr>
<td>4:05 – 4:25 pm</td>
<td>Questions</td>
<td></td>
</tr>
</tbody>
</table>
Keynote Presentation

"FIBI: Slide-Free Rapid and Non-Destructive Histology for Adequacy, Margins and Diagnosis"

Richard Levenson, MD
UC Davis Health

Committee Updates

- Jeffry Simko, MD, PhD
  University of California, San Francisco
- Peter Lucas, MD, PhD
  University of Pittsburgh
- Tan Ince, MD, PhD
  Weill Cornell Medicine

Disease Site Pathology Reports

Disease Site Pathologists

Questions & Discussion
NRG ONCOLOGY
CME/NON-CME AGENDAS
Brain Committee Workshop Agenda

Chair: Minesh Mehta, MD
Co-Chairs: Mark Gilbert, MD; Michael Vogelbaum, MD; Arnab Chakravarti, MD; Mei Polley, PhD

WORKSHOP AGENDA

NRG GBM PORTFOLIO: 15 MIN
A. NRG-BN001: Mehta/Gondi
B. NRG-BN007: Lassman
C. EAF 151: Tsien
D. NRG-BN010: Bagley
E. NRG-BN011: Iwamoto
F. A701702: Jing Wu

NRG BRAIN METASTASES PORTFOLIO: 18 MIN
A. NCCTG CE 7: Roberge
B. Alliance A071801: Wang
C. NRG-BN009: Gondi/Chan
D. NRG-BN012: Burri
E. NRG-CC003: Gondi
F. NRG-CC009: Gondi
G. S2000: Kotecha

NRG LOWER GRADE GLIOMA PORTFOLIO: 6 MIN
A. NRG-BN005: Grosshans
B. 1071 (Alliance CODEL): Vogelbaum

NRG OTHER TUMORS PORTFOLIO: 6 MIN
A. NRG-BN003: Rogers
B. ACNS 2021: NGGCT: Hall

NRG DEVELOPING TRIALS/NEW CONCEPTS: 75 MIN
A. LMD - P3 Proton CSI vs IFRT: Jonathan Yang
B. Brain Mets: ICI + SRS vs SRT: Rupesh Kotecha
C. Elderly nGBM PRDR: Jiayi Huang
Date: Saturday, July 23, 2022
Start and End Time: 11:30 am – 1:30 pm
Chair: Eleftherios Mamounas, MD
Co-Chairs: Julia White, MD; Charles Geyer, MD

Learning Objectives
Following this activity, participants will be better able to:

1. Identify and describe the design and status of new breast cancer clinical trials.
2. Identify and describe the status of ongoing breast cancer clinical trials.
3. Identify and describe new forms of radiotherapy delivery and their use in breast cancer trials.
4. Identify and describe systemic therapies, including chemotherapeutic drugs, hormonal strategies, biologic agents, new classes of targeted therapies, and immunotherapy that may be used in breast cancer treatment clinical trials.

WORKSHOP AGENDA

11:30 – 12:00  Report from the Breast Working Group Meeting
Eleftherios Mamounas, MD
Julia White, MD

12:00 – 12:15  BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Breast Cancer with a Low Oncotype Recurrence Score
Julia White, MD

12:15 – 12:30  BR008: A phase III randomized trial evaluating omission of breast radiotherapy for low-risk HER2-positive breast cancer
Lior Braunstein, MD

12:30 – 12:45  BR009: Chemotherapy plus ET vs. Ovarian Ablation plus ET in Early Stage Hormone-Positive Premenopausal Women with Oncotype ≤ 25 (OFSET CHEMO)
Eleftherios Mamounas, MD

12:45 – 12:55  ALLIANCE A011801: COMPASS HER2 Trials Examining Escalating and De-Escalating Therapy in HER2-Positive Breast Cancer: Optimizing Treatment in Residual Disease (COMPASS HER2 RD): A Double-Blinded, Phase III Randomized Trial
Virginia Borges, MD

12:55 – 1:10  BR004: A Randomized Phase III Trial of Taxane/Trastuzumab/Pertuzumab/Placebo Compared to Taxane/Trastuzumab/Pertuzumab/Atezolizumab in First Line HER2-Positive Metastatic Breast Cancer
Charles Geyer, Jr., MD

1:10 – 1:20  DESTINY BREAST-05 (NSABP B-60): DS-8201a vs. T-DM-1 for high risk patients with HER2-positive residual invasive cancer following preoperative therapy
Jame Abraham, MD

1:20 – 1:30  LidERA/NSABP-B-61: Giredestrant vs. Physician’s Choice ET in Medium/High-Risk ER+/HER2- Early-Stage Breast Cancer
Charles Geyer, Jr., MD
Canadian Members Subcommittee Meeting Agenda

Date: Thursday, July 21, 2022
Start and End Time: 11:00am – 12:00pm CST
Chair: Jean-Paul Bahary, MD
Vice-Chair: Al Covens, MD
NRG Oncology Operations: Erica Field (Back-up representatives: Judy Langer and Jessica Marston)

Learning Objectives:

Following this activity, participants will be better able to:

1. Discuss the status and significance of new and ongoing NRG Oncology clinical trials available in Canada
2. Discuss and subsequently apply standards and procedures required to participate in a research protocol supported by NRG Oncology
3. Learn about trials available in Canada

AGENDA

I. General
   a. Welcome, Introductions, Housekeeping – Committee chairs
   b. Overview of Workshop Agenda and Disclosures and Potential Conflict of Interest

II. NCI updates
   a. Status of consent form template for sites in Canada
   b. Protocol amendment timeline

III. Status of NRG Oncology Trials in Canada
   a. Accrual Update (January 1, 2022 – June 30, 2022)
      Discussion lead - NRG Oncology Regulatory
   b. Audit trends and remote auditing – Mary Jo Antonelli

IV. Optimizing Accrual in Canada
   a. Discuss best practices for and barriers to optimizing accrual among Canadian sites
      Discussion lead – NRG Regulatory and Canadian Subcommittee Co-Chairs

V. New Protocols
   a. Promotion of activated trial, NRG-CC009: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases from Small Cell Lung Cancer–Vinai Gondi, MD; Chad Rusthoven, MD

VI. New Business, General Questions, Discussion, Next Meeting
Learning Objectives
Following this activity, participants will be better able to:

1. Discuss proposed and ongoing NRG clinical trials on cancer prevention and control in each of the primary disease sites
2. Discuss proposed and ongoing NRG clinical trials on prevention and control in each of the four disciplines (disparities, chemoprevention, survivorship and biomarkers and early detection)
3. Discuss multi-disciplinary aspects of ongoing and proposed clinical trials in each of the primary disease sites
4. Identify and discuss the results and publication status of CPC clinical trials recently completed by NRG Oncology.
5. Identify and prioritize areas of unmet need in cancer prevention research in each of the primary disease sites
6. Apply standards and procedures required to design, submit, and conduct a research protocol for support by the NRG

A. CPC Announcements – Lisa Kachnic, MD

B. Results from NRG CPC Pilot Projects
   • Virtual Reality Nature Experiences as an Intervention for Cancer-Related Cognitive Impairment - Noël Arring, DNP, PhD, RN
   • Cognitive Behavioral Therapy for Insomnia in Patients with Glioma – Ashlee Loughan, PhD

C. Review of open CPC studies – CPC Chairs
   • NRG-CC005: (FORTE) Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
   • NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]
   • NRG-CC009: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases from Small Cell Lung Cancer

D. Developing Protocols and Concepts
   • STOP CIPN: Randomized Trial of Limb Cryocompression versus ConTinuous COMpression versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy – Kathryn Pennington, MD
   • A randomized phase II study of hypofractionated versus conventional fractionation radiotherapy in post-operative gynecological cancers evaluating late toxicities and quality of life – Eric Leung, MD
   • Endometrial cancer prevention in women with obesity with the levonorgestrel-releasing intrauterine system – Laurence Bernard, MD
   • A randomized phase 2 study comparing temporally-modulated pulsed radiation therapy (TMPRT) versus standard radiation therapy for elderly glioblastoma patients to prolong symptom deterioration-free survival – Jiayi Huang, MD
   • Ultra-Short Radiation Therapy for Patients Requiring Regional Nodal Irradiation – Frank Vicini, MD

E. Questions and Discussion
Cancer Care Delivery Research (CCDR) Meeting

Date: Thursday, July 21, 2022
Start and End Time: 10:00am – 12:00pm CST
Co-Chair: Mary E. Cooley, PhD, RN
Co-Chair: Matthew F. Hudson, PhD, MPH

Learning Objectives

Following this activity, participants will be better able to:
1. Discuss proposed and ongoing NRG cancer care delivery research trials.
2. Discuss proposed and ongoing NRG cancer care delivery research trials and cross-cutting aims with disparities.
3. Identify and prioritize areas of unmet need in cancer care delivery research.
4. Apply procedures required to design, submit, and implement a research protocol for support by the NRG.

<table>
<thead>
<tr>
<th>Welcome and Committee Updates</th>
<th>Mary Cooley, PhD, RN, CCDR Chair; Matthew Hudson, PhD, CCDR Vice-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multilevel Barriers and Facilitators to Sexual Orientation and Gender Identity Data Collection</td>
<td>Megan Mullins, PhD</td>
</tr>
<tr>
<td>in the National Cancer Institute Community Oncology Research Program (NCORP)</td>
<td></td>
</tr>
<tr>
<td>Institutional pilot project update: Implementation of guideline-based molecular profiling of</td>
<td>Andrea Hagemann, MD</td>
</tr>
<tr>
<td>early-stage endometrial cancer</td>
<td></td>
</tr>
<tr>
<td>Developing concept: A stepped wedge cluster randomized controlled trial comparing a navigation</td>
<td>Evan Graboyes, MD</td>
</tr>
<tr>
<td>based multi-level intervention with usual care to decrease delays among adults with locally</td>
<td></td>
</tr>
<tr>
<td>advanced head and neck squamous cell carcinoma</td>
<td></td>
</tr>
<tr>
<td>CCDR developing study/R01: A study to evaluate the effectiveness of WRITE Symptoms in</td>
<td>Heidi Donovan, PhD, RN</td>
</tr>
<tr>
<td>improving symptoms and function of individuals living with advanced gynecologic cancers.</td>
<td></td>
</tr>
<tr>
<td>NRG-CC007CD: Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors</td>
<td>Ron Chen, MD, NRG-CC007CD Study Chair</td>
</tr>
<tr>
<td>Who Receive Androgen Deprivation Therapy</td>
<td></td>
</tr>
</tbody>
</table>

QUESTIONS / DISCUSSION

ALL
Cervix Workshop Agenda

Date: Friday, July 22, 2022
Start and End Time: 8:00 am-10:00 am CST (in person only)
Chair: Charles A. (Trey) Leath, III, MD, MSPH
Co-Chair: Jyoti Mayadev, MD
Translational Co-Chair: Dmitriy Zamarin, MD, PhD

Learning Objectives:
Following this activity, participants will be better able to:
1. Discuss national and international priorities, goals and initiatives in the management of cervical cancer
2. Discuss currently active and developing NRG clinical trials on the prevention, diagnosis, and treatment of cervical and vulvar cancers
3. Discuss promising therapeutics in development and potential translational research objectives and strategies for future clinical trials
4. Apply standards and procedures needed to design, submit, (revise), and conduct a research protocol within the NRG
5. Outline both potential barriers and potential solutions to improve enrollment to NRG clinical trials in cervical and vulvar cancer to include international collaboration

WORKSHOP AGENDA

Scientific Developmental Focus

A. Introduction / Announcements (8:00-8:15 AM)
   a. Welcome, committee membership and rotation plan and review of Feb 2022 minutes
   b. Cervix updates from the task forces
      i. Cervical Cancer Task Force – Dana Chase (2nd Term), Katherine Moxley (1st Term)
      ii. Cervical Cancer Task Force (Junior Investigator) – Naresh Jegadeesh
      iii. Cervical cancer patient advocate: Madeline Kossik

B. Cervical Cancer Trials and Innovation (8:15am-9:00am)
   a. Cervical Cancer Clinical Trials Update and Path Forward (Jyoti Mayadev): 7 mins
   b. Update of NRG GY006 and Innovations in Progress/R01 update (Loren Mell): 7 mins
   c. Cervical Cancer status of ctHPV in clinical development and trials (Kathy Han): 10 mins
   d. GCIIG Clinical Trials Update (David Gaffney): 5 mins
   e. GOG-Partners Portfolio Update in Cervical Cancer (Leslie Randall): 10 mins

C. New Concepts (9:00am – 9:30am)

D. Previously committee approved/reviewed concepts – current updates and future directions (9:30am-9:50 AM)
   i. CV2040, Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Cervix and Uterus (SPARTACUS) II (Eric Leung)
   b. Concepts in Development

| CV2221 | A Randomized Phase II Trial of concurrent and adjuvant immunotherapy versus no immunotherapy in high-risk, local regionally advanced cervical cancer (Rimel, Moore, Naumann) |
| CV2218 | A Randomized Phase II/III trial of Bevacizumab, Tiramolumab and Atezolizumab versus Physician Choice Chemotherapy in PDL1 Positive Recurrent Cervical Cancer Previously Treated with Checkpoint Inhibitors. (Salani) |
| CV2219 | Risk Stratified Adjuvant Therapy with TKI and IO vs IO after chemoradiotherapy for Locally Advanced Cervical Cancer (Mayadev, Zamarin) |

N: 143-146
E. Closed Studies

Protocols: 101, 120, 205, 222, 141, 173, 179, 204, 206, 240, 233, 9806

F. Active / Recently Completed Trials

a. **GOG-0724/ROG0724**: Phase III trial randomized study of concurrent chemotherapy and pelvic RT with or without adjuvant chemotherapy in high-risk patients with early stage cervical carcinoma following radical hysterectomy. (Heidi Gray, Anuja Jhingran)
   i. Opened April 2009
   ii. Awaiting number of events to close
   iii. Planned Discussion – Does Outback impact decision to enroll?
   iv. Accrual 236/285 (82.8%)

b. **GOG-0263**: Randomized clinical trial for adjuvant chemoradiation in post-operative cervical cancer patients with intermediate risk factors (Sang Young Ryu, Kevin A)
   i. Opened April 2010
   ii. Amended Nov 2017 to decrease accrual from 534 to 360
   iii. Pending closure
   iv. Accrual 339/360 (94.2%)

c. **GOG-0274**: A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: GOG collaboration with the OUTBACK trial (ANZGOG 0902/GOG 0274 / RTOG 1174). (Kathleen Moore)
   i. Opened January 2012; NRG target accrual 500
   ii. Expanded target accrual to 900 patients
   iii. Accrual completed May 2017
   iv. Study closed 6/1/2017 – 924/900 accrued – NRG accrual 627
   v. ASCO Oral Presentation

d. **GOG-0278**: Evaluation of physical function and quality of life (QOL) before and after non-radical surgical therapy for stage IA1–IB1 (≤2cm) cervical cancer. (Al Covens)
   i. Opened October 1, 2012
   ii. PET imaging amendment approved July 2015
   iii. Accrual 220/220 (100%)

e. **GOG-0279**: A phase II trial evaluating cisplatin and gemcitabine concurrently with intensity-modulated radiation therapy (IMRT) for the treatment of locally advanced squamous cell carcinoma of the vulva. (Neil S. Horowitz)
   i. Opened July 2, 2012
   ii. Temporarily Closed June 15,2015 after enrolling 28 in 1st stage
   iii. 2nd stage re-opened July 2016
   iv. Accrual completed

f. **NRG-GY006**: A randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, stage II, IIIB, or IVA Cancer of the uterine cervix or Stage II–IVA vaginal cancer. (Trey Leath, Loren Mellon)
   i. Opened January 15, 2016
   ii. Amendment to CTEP re: increase in accrual size and transition to Randomized phase 3
   iii. Temporarily closed secondary to drug shortage May 28, 2021
iv. Accrual 396/450 (88.0%)

g. **NRG-GY017**: Phase I trial using anti PD-L1 (atezolizumab) as immune primer and concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer. (Jyoti Mayadev)
   i. Opened October 26, 2018
   ii. Accrual: 40/40
   iii. Presentation SGO 2022

Reports from Other Committees and Groups

h. Publications Subcommittee
i. Patient Centered Outcomes Research Committee
j. Ancillary Data Committee
k. Cancer Prevention and Control
l. Rare Tumor Committee
m. Vaccine Subcommittee
n. Pathology Committee
o. Radiation Committee
p. SPORE Committee
q. Nursing
r. Medical Oncology
s. Patient/Community/Advocacy

G. Concluding Remarks and Wrap-up

Next Semi-Annual Meeting – Chicago, IL July 21-23, 2022

QUESTIONS / DISCUSSION
Developmental Therapeutics Committee Agenda

Date: Thursday, July 21, 2022
Time: 12:30 pm - 2:30 PM CT
Chairs: Roisin O’Cearbhaill, MD (Dev. Therapeutics)
Translational Research Chair: Panagiotis Konstantinopoulos, MD, PhD (Dev. Therapeutics)
Co-Chairs: Floor Backes, MD (Phase II), Russell Schilder, MD (Phase I), Stephanie Gaillard, MD, PhD (Phase I)

Learning Objectives:
Following this activity, participants will be better able to:

1. Participants will become familiar with current status of translational research projects involving phase I and II studies that are under development or activated for accrual.
2. New concepts will be reviewed for approval or disapproval, including a discussion of trial design including multi-arm studies as well as preclinical and early clinical data related to investigational agents.
3. Participants will become familiar ComboMATCH Trial
4. Recommendations for action by the GYN Developmental Therapeutics committee will be summarized.

12:30 PM – 12:40 PM Introduction, Dr. O’Cearbhaill and Dr Backes. Welcome.
   Review of opportunities for new investigators and discuss committee rotation.

12:40 PM – 12:55 PM Update on concepts from last meetings and studies under development:
   See below for list

12:55 PM-1:15 PM Presentations new DT/phase I/safety lead in trials recently opened or soon to open:
   - GY027: Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Carboplatin and Paclitaxel with Ipatasertib in Epithelial Ovarian Cancer (Katherine Fuh)
   - GY012: update on toxicity and management of toxicity (Shannon Westin)

1:15 PM - 2:00 PM New Concepts: pending

2:00 PM – 2:10 PM Phase 1 committee updates (Gaillard/Schilder)

2:10 PM – 2:20 PM ComboMATCH update (O’Cearbhaill, NRG representative for the ComboMATCH)

2:20 PM-2:30 PM Open discussion, closing remarks

List of Studies

Active studies:

- **NRG-GY014**, A phase II study of tazemetostat (EPZ-6438) in recurrent endometrioid or clear cell carcinoma of the ovary, and recurrent or persistent endometrioid endometrial adenocarcinoma (Ramez Eskander)
  - Second stage amendment for ovarian clear cell cancer ARID1A mutant cohort reopened 2/7/22 and now closed to accrual
- **NRG-GY022**, Assessment of carboplatin clearance predictors: a companion PK study to NCI sponsored clinical trials or standard of care treatments using carboplatin (Sarah Taylor/Jan Beumer)
  - 206/250 enrolled, closed temporarily due to IV contrast shortage (45 needed)
Under development:

- **PI1966**, A phase IB study of combination WEE1 kinase (AZD1775) and ATR kinase inhibition (AZD6738) for the treatment of recurrent CCNE1 amplified ovarian and endometrial carcinomas (Simpkins) on hold
  - Discussion about plan for drug acquisition/supply
  - AZ not providing drug. In discussion with 1 CTEP drug and 1 other company (non-CTEP) to find drug supply
- **DT2059**: Phase 1/2 M3814 plus hypofractionated radiation followed by M3814 plus avelumab in recurrent cervical cancer (Henson/Moore)
  - **Preclinical completed**
  - **RSC 2/2022 approved**
  - **disapproved for further development due to lack of drug supply and interest by company**
- **GY027/PI2054** Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Carboplatin and Paclitaxel with Ipatasertib in Epithelial Ovarian Cancer (Fuh/Moore)
  - **PTMA #100805**
  - **Submitted to CTEP 10/20, CRF build NACT/IDS ongoing in protocol development**
  - **Feb activation (drop dead 02/11 extended to July 2022)**
- **GY028/UC2055 (UC2055/PTMA #100828)** Phase IB and randomized phase II trial of medroxyprogesterone acetate +/- ipatasertib in recurrent/metastatic endometrioid endometrial cancer (Onstad/Westin)
  - **PTMA #100828**
  - **Protocol under development**
- **DT2106** A Phase IB study of combination BET protein inhibition and ATR kinase for the treatment of recurrent ARID1A mutated clear cell and endometrioid ovarian and endometrial carcinomas (Fiona Simpkins).
  - Updated with new BET and ATR inhibitors
  - Call with CTEP IDB 9/20/21, RSC approved Oct 2021
  - Call with Biomarker review committee 3/31/22
- **PI2132** A Phase Ib/II Study of adavosertib combined with carboplatin in women with primary platinum-resistant TP53-mutated ovarian, fallopian tube, or primary peritoneal carcinoma with and without CCNE1 amplifications. (Washington/Moore)
  - **RSC 2/16/22**
  - Medical oncology chair is new (young investigator Abdul Rafeh Naqash)
  - Need call with CTEP
- **PI2134** A Multi-Arm, Non-Comparative Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Carboplatin and Paclitaxel in Combination with Magrolimab, ZEN003694, or Birinapant in Epithelial Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer (Haggerty/Martin/ Arend/Moore/ Zhang/Annunziata)
  - **RSC approved 11.3.21**
  - **N=78**
  - Lack of drug supply – will not be further developed.
- **PI2140** A Phase IB study of the combination SM08502 CLK inhibitor and weekly paclitaxel in recurrent endometrial carcinoma. (Corr) Reviewers: Gray/Ulahannan/Jain
  - Company in discussion with CTEP to become a CRDA drug – NeXT application going in mid-February per Dr Corr

Safety lead-in under development

- **NRG-GY025** A randomized phase II trial of immunotherapy with dual immune checkpoint inhibitors compared to antiPD1 monotherapy in patients with deficient mismatch repair system recurrent endometrial carcinoma (Mahdi) – currently open for safety lead in
NRG-GY026 A randomized phase II/III trial of paclitaxel/carboplatin alone or combined with either trastuzumab or trastuzumab/pertuzumab in HER2 Positive Stage I-IV uterine serous carcinoma and carcinosarcoma after primary surgery (Erikson, Fader)

NRG-GY029: A Randomized Phase II trial comparing the combination of PI3K inhibitor Copanlisib and PARP inhibitor Olaparib to standard chemotherapy in patients with recurrent platinum resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have progressed through prior PARP inhibitor therapy (Konstantinopoulos)
  - Will have safety lead in
  - Protocol writing/developing phase

OV2135: Randomized Phase II of Paclitaxel /Carboplatin +/- Selinexor in Ovarian, Tubal, Peritoneal Carcinoma characterized as homologous recombination proficient (HRp) (Arend, Moore)
  - RSC 2/16/22

Active Phase I Studies (including safety lead-ins):

NRG-GY022 Assessment of Carboplatin Clearance Predictors: A PK Study to NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin (Taylor/ Beumer)
  - Accrual for female participants completed, temporarily closed to accrual (45 male participants needed)

Active Phase II Studies (including safety lead-ins):

Ovarian Cancer and Endometrial cancer studies:

NRG-GY012, A Randomized Phase II Study Comparing Single Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. (Mackay) completed DT safety review

Ovarian Cancer Studies (prior safety lead-in):

Closed

NRG-GY009 (PTMA/CRDL) A randomized, phase II/III study of pegylated liposomal doxorubicin and atezolizumab versus pegylated liposomal doxorubicin/bevacizumab and atezolizumab versus pegylated liposomal doxorubicin/bevacizumab in platinum resistant ovarian cancer (O’Cearbhaill) Phase II completed accrual May 2019. Phase III completed accrual October 2021

NRG-GY014 A phase II study of tazemetostat (EPZ-6438) in recurrent endometrioid/clear cell carcinoma of the ovary, and recurrent endometrioid endometrial adenocarcinoma (R Eskander) CTEP CRDL LOI. First stage completed accrual August 2019

NRG-GY021 A randomized phase II trial of olaparib versus olaparib + tremelimumab in platinum-sensitive recurrent ovarian cancer (Adams)
  →Safety lead-in closed March 2021, study permanently closed
  Toxicity limited further enrollment and analyzing data

Closed DT/Phase I studies:

Cervical Cancer Studies:

NRG-GY017 Anti PD-L1 (atezolizumab) as an immune primer and concurrently with extended field chemoradiotherapy for node positive locally advanced cervical cancer. (Mayadev/ Schilder/Zamarin) Safety lead-in – completed. Study closed. Plenary at SGO 2022
Endometrial Cancer Studies:

Ovarian Cancer Studies:

- **NRG-GY007** A phase I/II study of ruxolitinib with front-line neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (Landen) **Completed accrual.** Presented at ASCO 2022
Radiation Developmental Therapeutics Workshop Agenda

Date: Monday, July 18, 2022
Start and End Time: 3:30 pm - 5:00 pm
Chairs: Steven Lin, MD PhD and Sandip Patel, MD

Learning Objectives
Following this activity, participants will be better able to:
1. Critically appraise optimal statistical designs for phase I trials
2. Evaluate the landscape of early phase drug-radiation combination studies at the NRG

WORKSHOP AGENDA
I. Introduction
   A. General Business
      Steven Lin, M.D., PhD

II. Scientific Talk: Trial Design Considerations
    Sandip Patel, MD

III. DTRT White Paper
     Zachary Zumsteg, MD and Siddarth Sheth, MD

IV. Disease Site and Working Group Updates (ongoing and developing protocols)
   a. Brain/CNS (Committee Liaison: Vinay Puduvalli, MD)
      i. BN010: A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma. (PI: Stephen J. Bagley, MD, MSCE)
         1. Activated July 6, 2021; enrollment =2
      ii. Concept BN2123: Phase 1/1b trial of combination high-dose methotrexate, rituximab, temozolomide, plus selinexor (MR-TS) followed by investigator’s choice consolidation for newly diagnosed primary CNS lymphoma (PCNSL) (PI: Yazmin Odia, MD)
         1. RSC approval October 2021
   b. Sarcoma Working Group (WG Liaison: Meng Welliver, MD)
      i. DT001: A Phase IB Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS) (Meng Welliver, MD)
         1. Cohort A enrolled to all 3 DL, no DLT—next steps to be discussed; cohort B enrolling
   c. Genitourinary (Committee Liaison: Zachary Zumsteg, MD and Chad Tang, MD)
      i. GU007— Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with INITIAL Phase I) (PI: Dror Michaelson, MD)
         1. Dose level 2 completed; Dose level 3 OPEN
   d. Head and Neck (Committee Liaison: Siddarth Sheth, MD)
      i. HN008: Ph I Trial with Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients with Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (PI: Maura Gillison MD, Michael Samuels MD); Activated: 12/10/2020; Enrollment: 3/42 patients
   e. Breast (Committee Liaison: Steve Chmura, MD)
   f. Lung (Committee Liaison: Steven Lin, MD, PhD)
      i. LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined with MEDI4736 (Durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1) (PI: Steven Lin, MD, PhD)
         1. To be amended with additional arms
   g. GI-non colorectal (Committee Liaison: Terence Williams, MD)
      i. GI007: Phase I trial with Expansion Cohort of OBP-301 (telomelyn) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma Who Are Not Candidates for Surgery (PI: Geoffrey Ku, MD) Accrual=3
      ii. Concept GI2128: A Phase I Trial of Dose Escalated Radiation in 5 or 15 Fractions for Locally Advanced Pancreas Cancer (LAPC) Patients (PI: Nina Sanford, MD)
   h. GI-colorectal (Committee Liaison: Theodore Hong, MD)
      i. GYN (Committee Liaison: Jyoti Mayadev, MD)
Genitourinary Cancer Workshop Agenda

Date: Saturday, July 23, 2022
Start and end time: 7:30 am – 9:00 am
Chair: Felix Feng, MD
Co-Chairs: Jason Efstathiou, MD; Todd Morgan, MD; Howard Sandler, MD, Oliver Sartor, MD

Learning Objectives
Following this activity, participants will be better able to:

1. Recognize critical aspects of developing and conducting a clinical trial in genitourinary (GU) cancer therapy research in a cooperative group setting.
2. Identify and describe the design and status of new GU cancer clinical trials being planned and launched by NRG Oncology, to enable contribution to protocol design vetting and/or effective patient enrollment in newly-launched studies.
3. Identify and describe the status of ongoing GU cancer clinical trials being conducted by NRG Oncology, to enable effective patient enrollment in and treatment on these trials, and proper collection, submission and/or evaluation of the required patient data.
4. Identify, describe, and analyze aspects of ongoing NRG Oncology GU clinical trials which are in need of special support and improvement, to enable effective patient enrollment in and treatment on these trials, and proper collection, submission and/or evaluation of the required patient data.
5. Identify and discuss the results and publication status of GU cancer clinical trials recently completed by NRG Oncology, so they can make informed decisions based on the state of the science regarding patient treatment, and they can relay study results to patients treated on these trials.
6. Identify and describe new forms of radiotherapy delivery and their use in NRG Oncology GU cancer trials.
7. Identify and describe systemic therapies, including chemotherapeutic drugs, hormonal strategies, biologic agents, and new classes of targeted therapies that may be used in conjunction with radiation therapy in GU cancer treatment, and the effectiveness of those agents as demonstrated in NRG Oncology clinical trials.
8. Identify and describe new developments in biologic and imaging science that can be used in translational research strategies to identify GU cancer patient subgroups at risk for failure with existing treatments and identify new approaches for these patients.

WORKSHOP AGENDA
8:00 – 8:05 Opening Remarks and Update
8:05 – 9:30 Review of Active Trials

NRG GU002 Phil-III Adjuvant RT Following Radical Prostatectomy ± Adjuvant Docetaxel (RADD trial) Mark Hurwitz, MD
NRG GU005 Phase III IGRT & SBRT vs. IGRT & Hypofrach IMRT localized prostate cancer Rod Ellis, MD
NRG GU007 Phase I/IIR of RT + ADT +/- the PARP inhibitor Niraparib for patients with high-risk prostate cancer Dror Michaelson, MD, PhD Zach Zunsteg, MD
NRG GU008 Androgen Deprivation Therapy With or Without Radiation Therapy or Docetaxel in Patients With Node-Positive Prostate Cancer: A Phase III Randomized Trial Ronald Chen, MD, MPH
NRG GU009 (PREDICT-RT) Parallel Phase III Randomized Trials for High Risk Prostate Cancer Testing Treatment De-Intensification for Men with Lower Genomic Risk and Treatment Intensification for Men with High Genomic Risk (PREDICT-RT) Paul Nguyen, MD; Oliver Sartor, MD
RTOG 3506 Randomized Phase II Trial of Salvage Radiotherapy With Std vs Enhanced ADT (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences With Aggressive Disease Features (STEEL trial) Edwin Posadas, MD Hiram Gay, MD
NRG GU010 (GUIDANCE) Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-intensification and Intensification Clinical Trial (GUIDANCE) Neil Desai, MD; Ale Berlin, MD PhD

NRG GU011 Phase II trial of PROstate oligoMETastastic radiotHERapy with or without ANdrogen deprivation therapy (NRG PROMETHEAN). Bridget Koontz, MD

SWOG/NRG 1806 Chemoradiation +/- ImmuneCheckpoint Blockade for Bladder Cancer Jason Efstathiou, MD

ECOG/NRG EA8185 Phase 2 Study of Bladder-Sparing ChemoradiatioN with Durvalumab in Clinical Stage 3, node Positive URothElial Carcinoma (INSPIRE) Abhishek Solanki, MD MS Jason Efstathiou, MD

SWOG 1802 Local therapy for M1 prostate cancer, a SWOG study Richard Valicenti, MD

EA8183 Phase III Double Blinded Study of Early Intervention After RADICAL ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE). Alicia Morgans, MD

EA8191 Phase III Study of Local or Systemic Therapy Intensification Directed in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE) Neha Vapiwala, MD Bridget Koontz, MD

9:30 – 9:40 Review of Pending Studies

NRG GU012 (SAMURAI) Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (“SAMURAI”) Bill Hall, MD Rana McKay, MD

9:40– 9:55 Other issues

Translational Research Phuoc Tran, MD PhD
Medical Oncology Update Oliver Sartor, MD
Urology Update Todd Morgan, MD
New Business Group

9:55 – 10:00 Closing Remarks
i. DT2059: Phase I/2 M3814 plus hypofractionated radiation followed by M3814 plus avelumab in recurrent cervical cancer (PIs: Henson/Moore)

QUESTIONS / DISCUSSION
**GI Colorectal Cancer Subcommittee Agenda**  
**(CLOSED Mtg)**

| Date: | Saturday, July 23, 2022 |
| Time: | 9:15 – 10:30 am CST |
| Colorectal Chair: | Thomas George, MD, FACP |
| Colorectal Co-Chair: | Scott Kopetz, MD, PhD |

**Learning Objectives**  
Following this activity, participants will be better able to:

1. Appreciate the eligibility criteria and hypotheses being explored in current and upcoming GI Onc clinical trials

**Discussion/Study Information**

**Introduction and Opening Remarks**

*Speaker*  
Thomas George, MD  
Scott Kopetz, MD, PhD

**Updates from Committee Liaisons**

**Update on Protocol Eligibility Template**

**Working Group Functions & Updates**

| Colon Working Group | Christina Wu, MD  
Scott Kopetz, MD, PhD |
|---------------------|----------------------|
| CC-005 (FORTE) | Five or Ten-Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps  
Robert Schoen, MD |
| NRG-GI005 (COBRA) | ctDNA as a decision tool for stage II colon cancer treatment  
Van Morris, MD |
| NRG-GI008 (CIRCULATE-US) | ctDNA as decision tool for stage III colon cancer treatment  
Arvind Dasari, MD |
| NRG-GI004/S1610 (COMMIT) | MSI-H mCRC 1L Immunotherapy Study  
Caio Rocha Lima, MD |
| A022101/NRG-GI009 (ERASur)* | Oligo mCRC Total Ablative Therapy  
Paul Romesser, MD  
Kate Hitchcock, MD, PhD  
Eric Miller, MD, PhD |

<table>
<thead>
<tr>
<th>Rectal Working Group</th>
<th>Kate Hitchcock, MD, PhD</th>
</tr>
</thead>
</table>
| A022104/NRG-GI010 (JANUS)* | Watch & Wait vs. TME after optimal TNT  
William Hall, MD |
| SOLO Trial | NEW CONCEPT: SCRT vs. LCRT as part of TNT  
Glen C. Balch, MD, MBA |
| NRG-CR2103(2) | REVISED CONCEPT: ATRi w/ chemoRT for Rectal Ca  
Eric Miller, MD, PhD  
Terry Williams, MD, PhD |

<table>
<thead>
<tr>
<th>NET Working Group</th>
<th>Heloisa Soares, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>New NET Concepts or Study Concerns</td>
<td></td>
</tr>
</tbody>
</table>

---

NRG Oncology Meeting - July 2022
GI Non-Colorectal Cancer Subcommittee Agenda

Date: Saturday, July 23, 2022
Time: 10:45 – 12:15 am CST
Non-Colorectal Chair: Ted Hong, MD
Non-Colorectal Co-Chair: David Ilson, MD

Learning Objectives
Following this activity, participants will be better able to:

1. Appreciate the eligibility criteria and hypotheses being explored in current and upcoming GI Onc clinical trials

Discussion/Study Information

<table>
<thead>
<tr>
<th>Introduction and Opening Remarks</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ted Hong, MD</td>
</tr>
</tbody>
</table>

Updates from Committee Liaisons

Working Group Updates

<table>
<thead>
<tr>
<th>Working Group</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anal Working Group</td>
<td>Jenny Dorth, MD</td>
</tr>
<tr>
<td>Background</td>
<td></td>
</tr>
<tr>
<td>Concepts in Development</td>
<td></td>
</tr>
<tr>
<td>Brainstorm</td>
<td></td>
</tr>
<tr>
<td>Hepatobiliary Working Group</td>
<td>Eugene Koay, MD, PhD</td>
</tr>
<tr>
<td>Background</td>
<td></td>
</tr>
<tr>
<td>Concepts in Development</td>
<td></td>
</tr>
<tr>
<td>Brainstorm</td>
<td></td>
</tr>
<tr>
<td>Esophagogastric Working Group</td>
<td>Salma Jabbour, MD</td>
</tr>
<tr>
<td>Background</td>
<td></td>
</tr>
<tr>
<td>Concepts in Development</td>
<td></td>
</tr>
<tr>
<td>Brainstorm</td>
<td></td>
</tr>
<tr>
<td>Pancreas Working Group</td>
<td>Nina Sanford, MD</td>
</tr>
<tr>
<td>Background</td>
<td></td>
</tr>
<tr>
<td>Concepts in Development</td>
<td></td>
</tr>
<tr>
<td>Brainstorm</td>
<td></td>
</tr>
</tbody>
</table>

NRG Oncology Meeting - July 2022
GYNECOLOGIC CANCER COMMITTEE AGENDA

Date: Saturday, July 23, 2022
Start and End Time: 7:45 AM – 9:30 AM
Chair: Carol Aghajanian, MD
Co-Chairs: Paul DiSilvestro, MD & David Gaffney, MD, PhD
Translational Science Co-Chair: Heather Lankes, PhD, MPH

Learning Objectives:
Following this activity, participants will be better able to:
1. Discuss the status and significance of new and ongoing clinical trials on the prevention, diagnosis, and treatment of gynecologic cancers.
2. Discuss promising translational research objectives and priorities for future clinical trials.
3. Apply standards and procedures required to design, submit and conduct a research protocol for support by NRG Oncology.
4. Assure strict quality control of gynecologic cancer clinical trials.

WORKSHOP AGENDA
I. General Business
   a. Call to order
   b. Symposia (Alvarez)

II. Committee Descriptions
   Gynecologic Cancer Committee
   Cervix/Vulvar Cancer Subcommittee
   • Cervical cancer – Randomized phase II, Phase II/III, Phase III
   • Vulvar cancer – Phase II, Randomized phase II, Phase II/III, Phase III
   Ovarian Cancer Subcommittee
   • Ovarian cancer (Ovarian cancer = Fallopian tube cancer, Ovarian cancer, Primary Peritoneal Cancer)
     ➢ Neoadjuvant chemotherapy (NACT) – Randomized phase II
     ➢ Randomized phase II, Phase II/III, Phase III
   Rare Tumor Subcommittee
   • Clear Cell Tumors
   • Germ Cell Tumors
   • Ovarian - Low Grade Serous
   • Ovarian - Mucinous
   • Ovarian - Stromal Tumors
   Uterine Corpus Cancer Subcommittee
   • Endometrial cancer
     ➢ Randomized phase II, Phase II/III, Phase III
   • Uterine sarcoma (leiomyosarcoma)
     ➢ Randomized phase II, Phase II/III, Phase III
   • Gestational trophoblastic neoplasm (GTN)
   GYN Developmental Therapeutics Committee
   • Early phase trials (Phase I, Phase I/II, Phase II), Window of opportunity trials
     ➢ Cervical cancer
     ➢ Endometrial cancer
     ➢ Ovarian cancer
     ➢ Uterine sarcoma
   GYN Phase I Subcommittee
Safety lead-ins
Phase I

Other NCTN Group Trials & Study Champions

**S1609, DART**: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

**AGCT1531**, A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors. *This is an Adolescent and Young Adult (AYA) Study: Available to COG and the Adult Groups*

**NRG Oncology Study Champion: Covens**

**AGCT1532**, A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors. *This is an Adolescent and Young Adult (AYA) Study: It is available to COG and the Adult Groups*

**NRG Oncology Study Champion: Covens**

**Small Cell Neuroendocrine, First line (NCTN, SWOG): S2012**: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

**NRG Oncology Study Champion: Mahdi**

**Small Cell Neuroendocrine, Second line (ETCTN, LAO-CT018): 10315**: A Phase 2 Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas

*Closed to Accrual as of 7/26/21*

**A091903**, A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma

Alliance, Phase III trial of TMZ + olaparib v. physician choice of pazopanib or trab, measurable disease, uterine LMS (*Not yet activated*)
III. Cervix/Vulvar Cancer Subcommittee

New Concepts

a. **CV2226**, PAROLA – PAr-aortic LymphAdenectomy in Locally Advanced Cervical Cancer (Frumovitz)

b. **CV2227**, A phase II trial of EGFR inhibitor maintenance following definitive cisplatin-sensitized radiation for locally advanced cervical cancer (Oladoapo, Mayadev)

Studies Under Development

a. **CV2217**, A Randomized Phase II trial of combination immunotherapy with Nivolumab and Chemotherapy, versus Ipilimumab and Nivolumab with chemotherapy with, or without bevacizumab

b. **CV2218**, A Randomized Phase II/III trial of Bevacizumab, Tiragolumab and Atezolizumab versus Physician Choice Chemotherapy in PDL1 Positive Recurrent Cervical Cancer Previously Treated with Checkpoint Inhibitors

c. **CV2219**, Risk Stratified Adjuvant Therapy with TKI and IO vs IO after chemoradiotherapy for Locally Advanced Cervical Cancer

d. **CV2220**, A Randomized Phase II Study of the Integration of Radiotherapy into Chemotherapy and Pembrolizumab/bevacizumab in Newly Diagnosed Stage IVB Cervical Cancer

e. **CV2221**, A Randomized Phase II Trial of concurrent and adjuvant immunotherapy versus no immunotherapy in high-risk, local regionally advanced cervical cancer

Active Studies:

a. **NRG-GY006**, A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer (Charles Leath)

b. **NRG-GY024**, Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial (Brian Slomovitz)

Closed Studies, primary manuscript NOT published (Cervix): RTOG-0724, GOG-0263, GOG-0279

Closed Studies, primary manuscript NOT published (DT): GY017 (SGO 2022)

Closed Studies, primary manuscript NOT published (Outside Group): THE OUTBACK TRIAL (ANZGOG 0902/GOG 0274/RTOG 1174) – ASCO 2021

Closed studies, primary manuscript published (Outside Group): 270 (GROINSS-V) - JCO

Terminations:

IV. Ovarian Cancer Subcommittee

New Concepts

Studies Under Development

a. **NRG-GY029**, A Randomized Phase II trial comparing the combination of PI3K inhibitor Copanlisib (BAY 80-6946) and PARP inhibitor Olaparib (AZD2281) to standard chemotherapy in patients with recurrent platinum resistant ovarian, fallopian tube, or primary peritoneal cancer who have progressed through prior PARP inhibitor therapy (Panagiotis Konstantinopoulos)

b. **OV2206**, Randomized Phase 2 Trial of Weekly Paclitaxel with or without Tolinapant for Platinum Resistant, Recurrent Epithelial Ovarian Cancer (Kristen Zeligs, Christina Annunziata)

Active Studies:

a. **NRG-GY023**, A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab (Jung-Min Lee)
Rare Tumor Subcommittee – Ovarian

Studies Under Development

a. **RT2141**, Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in combination with Leuprolide Acetate and Exemestane in Recurrent AR Positive Adult-Type Ovarian Granulosa Cell Tumor (Elizabeth Hopp, Janet Rader)

Active Studies:

a. **NRG-GY019**, A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low Grade Serous Carcinoma of the Ovary or Peritoneum (Amanda Nickles Fader)

GYN Developmental Therapeutics Committee – Ovarian Cancer

New Concepts

Studies Under Development

a. **NRG-GY027**, Phase I/Ib safety and pharmacodynamic study of neoadjuvant (NACT) paclitaxel and carboplatin with ipatasertib as initial therapy of ovarian cancer PTMA 100805 (Katherine Fuh, Kathleen Moore)

b. **DT2106**, A Phase 1B study of combination ATR (M6620) and BET inhibition (ZEN-3694) to exploit ARID1A loss in recurrent ovarian and endometrial cancer (Fiona Simpkins)

c. **PI1966**, A phase I study of combination WEE1 kinase (AZD1775) and ATR kinase inhibition (AZD6738) for the treatment of recurrent CCNE1 amplified ovarian and endometrial carcinomas (Fiona Simpkins)

Active Studies:

a. **NRG-GY014**, A phase II study of tazemetostat (EPZ-6438) in recurrent endometrioid or clear cell carcinoma of the ovary, and recurrent or persistent endometrioid endometrial adenocarcinoma (Ramez Eskander, Alison Schram)

Closed Studies, primary manuscript NOT published (Ovarian): GY005, GY007 (ASCO 2022), GY009, GY021

Closed Studies, primary manuscript NOT published (Rare Tumor): 264 (IGCS 2020), 268 (ASCO 2016), 283, GY016 (IGCS 2022)

Closed Studies (primary manuscript published): 213, 262, GY003

Terminations:

V. Uterine Corpus Cancer Subcommitee

New Concepts

a. **UC2228**, Salvage SBRT with Concurrent Pembroliuzumab and Lenvatinib for Oligometastatic Endometrial Cancer: A Phase IIR Clinical Trial. (Barry)

b. **UC2229**, Evaluating a Molecular based protocol for EaRly stage high-intermediate risk Endometrial carcinomas directed by ctDNA: The EMERGE-C Trial. (Kuroki, Lee, Pothuri, Secord, Hacker)

c. **UC2230**, Phase II Study of Single-Agent (anti PD-L1) Pembrolizumab in MSI-H Early-Stage Endometrial Cancer Patients Desiring Fertility Preservation (Covens)

Studies Under Development

a. **NRG-GY026**, A phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oyxk (HERCEPTIN HYLECTA) or pertuzumab, trastuzumab, and hyaluronidase-zxzf (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcosarcoma (Britt Erickson)

b. **NRG-GY028** (PTMA#100828), Phase IB and Randomized Phase II trial of medroxyprogesterone acetate with or without ipatasertib in recurrent/metastatic endometrioid endometrial cancer (Michaela Onstad Grinsfelder, Shannon Westin)
c. **UC2043**, A Pilot Study of Dactinomycin plus Avelumab as First line Treatment for Selected Patients with Gestational Trophoblastic Neoplasia (Lua Eiriksson)

d. **UC2108**, Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Women with Advanced or Recurrent AR Positive ER Low Endometrial Cancer (Katherine Kurnit)

e. **UC2120**, A Phase III Randomized Trial of PD1/PDL1 inhibitor +/- radiation or chemotherapy inhibitor for Newly Diagnosed Completely Resected Stage III-IVA or recurrent chemo naïve Mismatch Repair Deficient (dMMR) Endometrial Cancer (Floor Backes)

f. **UC2142**, Neoadjuvant chemotherapy versus primary debulking surgery using molecularly targeted adjuvant therapy for advanced stage endometrial cancer (Emma Rossi, Victoria Bae-Jump)

g. **UC2208**, Tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (TAPER)/Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO POLEmut BLUE) A CCTG trial (Jessica McAlpine, Kathy Han)

h. **UC2210**, Prospective Phase II Trial of Volume-Directed Salvage Radiation Therapy and Pembrolizumab for Mismatch Repair Deficient Recurrent Endometrial Cancer. GOG-0238R (Matt Harkenrider)

i. **UC2214**, Prospective Phase II Trial of Volume-Directed Salvage Radiation Therapy and Chemotherapy for p53 Abnormal and No Specific Molecular Profile Recurrent Endometrial Cancer. GOG-0238R (Matt Harkenrider)

---

**Active Studies:**

a. **NRG-GY012**, A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer (Helen Mackay)

b. **NRG-GY018**, A randomized phase III Placebo-Controlled Study of Pembrolizumab in addition to Paclitaxel and Carboplatin for Measurable Stage III Or IVA, Stage IVB or Recurrent Endometrial Cancer (Ramez Eskander)

c. **NRG-GY020**, Randomized phase III trial of radiation +/- pembrolizumab for high intermediate risk mismatch repair deficient (dMMR) endometrioid endometrial cancer (Floor Backes)

d. **NRG- GY025**, A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma (Haider Mahdi)

---

**GYN Developmental Therapeutics Committee – Uterine Corpus Cancer**

**New Concepts**

a. **Studies Under Development**

a. **PI2140**, A Phase IB study of the combination SM08502 CLK inhibitor and weekly paclitaxel in recurrent endometrial carcinoma (Bradley Corr, Rebecca Arend)

---

**Closed Studies, primary manuscript NOT published (Corpus):**

- 238 (IGSC 2022)
- 286B (SGO 2020)

**Closed Studies (Primary manuscript published):**

- 188, 258

**Terminations:**

---

VI. **Developmental Therapeutics Committee** (O’Cearbhaill, Backes, Konstantinopoulos, Gaillard)

**Studies Under Development**

a. **MATCH COMBO**
• EAY191-N2, Phase 2 trial of fulvestrant and binimetinib in patients with hormone receptor-positive metastatic breast cancer with a frameshift or nonsense mutation or genomic deletion in NF1 (Bora Lim, Roisin O’Cearbhaill)

• EAY191-N4, A randomized trial of selumetinib and olaparib or selumetinib alone in patients with recurrent or persistent RAS pathway mutant ovarian and endometrial cancers (Shannon Westin)

• EAY191-N5, A randomized trial of neratinib, a pan-ERBB inhibitor, alone or in combination with palbociclib, a CDK4/6 inhibitor, in patients with HER2+ gynecologic cancers and other solid tumors (Haider Mahdi)

Active Studies:

a. NRG-GY022, Assessment of carboplatin clearance predictors: a companion PK study to NCI sponsored clinical trials or standard of care treatments using carboplatin (Sarah Taylor, Jan Beumer)

VII. Patient Centered Outcomes Research (PCOR) Committee Report (Wenzel)

VIII. Elderly & Special Populations Working Group and Cancer Care Delivery (Health Disparities Committee) (Tew)

IX. Translational Science Committee Report (Birrer, Lankes)

X. Cancer Prevention and Control Committee Report (Walker)

Studies Under Development

a. NRG-CC010, Impact of SLN mapping vs lymphadenectomy on lower extremity limb dysfunction in pts with endometrial cancer (Edward Tanner)

Active Studies:

a. NRG-CC008, A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROC) (Joan Walker, Warner Huh)

Closed Studies:

a. GOG-278, Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (=/<2CM) Cervical Cancer
Head and Neck Workshop

Date: Friday, July 22, 2022
Start and End Time: 4:45 PM – 6:15 PM CT
Chair: Sue Yom, MD, FACR, FASTRO, FAAWR
Co-Chair: Erich Sturgis, MD, MPH; Stuart Wong, MD

Learning Objectives:
Following this activity, participants will be better able to:

1. Develop new head and neck cancer trials to be conducted through the NRG Oncology network, specifically those testing (1) the addition of novel systemic therapies (chemotherapy, targeted therapy, immunotherapy) to radiation, (2) novel surgical or radiation approaches, (3) novel imaging approaches or (4) strategies to mitigate treatment related toxicity.
2. Develop strategies to enable effective patient enrollment on these trials and proper collection, submission and/or evaluation of the required patient data.
3. Apply the results of completed NRG Oncology trials to daily treatment decision making in order to optimize patient care.

WORKSHOP AGENDA

A. Head and Neck portfolio overview

B. Actively developing studies

• HN010 trial: Randomized phase II trial of docetaxel and HER2 targeted therapies in HER2 positive recurrent/metastatic salivary duct/salivary gland cancers
  Alan Ho, MD, PhD

• NRG-HN2138 concept: Biomarker-guided phase III trial of PD-1 inhibition with LAG3 inhibition as maintenance therapy after first-line platinum-gemcitabine -PD1 inhibition for recurrent/metastatic nasopharyngeal carcinoma
  Brigette Ma, MD

• NRG-HN2139 concept: Randomized phase II trial of chemo-immunotherapy vs. immunotherapy vs SOC in patients with recurrent/persistent PD-L1 enriched SCCHN undergoing salvage surgery
  Nabil Saba, MD

• NRG-HN2201 concept: Randomized phase I/III trial of RT and SMAC mimetic vs. cetuximab in LA HNSCC patients with cisplatin contraindication
  Loren Mell, MD

C. Review of active studies

Actively accruing trials

<table>
<thead>
<tr>
<th>Trial Code</th>
<th>Trial Description</th>
<th>Principal Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG-HN008</td>
<td>Phase I RT + DNA-PK inhibitor in cisplatin-ineligible patients with high risk LA HNSCC</td>
<td>Maura Gillison</td>
</tr>
<tr>
<td>NRG-HN009</td>
<td>Phase II-III RT with high-dose cisplatin (100 mg/m² x 3) vs weekly cisplatin (40 mg/m² x 7) for locoregionally advanced HNSCC</td>
<td>Paul Harari</td>
</tr>
<tr>
<td>RTOG 3507</td>
<td>Phase II - ReRT +/- Pembrolizumab in Locoregionally recurrent HNSCC</td>
<td>Stuart Wong</td>
</tr>
<tr>
<td>NRG-HN001</td>
<td>Individualized NPC treatment based on post-RT EBV DNA (Phase III)</td>
<td>Nancy Lee</td>
</tr>
<tr>
<td>NRG-HN005</td>
<td>Phase II-III of reduced field RT +/- systemic therapy for good risk HPV(+) cancer</td>
<td>Sue Yom</td>
</tr>
<tr>
<td>NRG-HN006</td>
<td>Phase II-III SLN Biopsy vs. END in T1-2N0 oral cavity cancer</td>
<td>Stephen Yom</td>
</tr>
<tr>
<td>RTOG 1216</td>
<td>RT+cisplatin vs. RT+docetaxel+cetuximab vs. RT+cisplatin+atezolizumab for “high risk” resected HNSCC (Phase III)</td>
<td>Julie Bauman, Paul Harari, David Rosenthal</td>
</tr>
</tbody>
</table>

D. Report on publications and protocols closed to active accrual

Temporary Closure
NRG-HN004  Phase II-III RT+ Cetuximab vs. RT + PD-L1 antibody in patients who cannot tolerate cisplatin with locally advanced HNSCC  Loren Mell

Recently completed

NRG-HN007  Phase III Gem/Cis vs. Gem/Cis/Nivo in 1st line rec/met NPC  Brigette Ma

E. NRG Core and General Membership  Sue Yom, MD

F. NRG Championed Trials updates  Sue Yom, MD

G. HNC Translational activities  Neil Hayes, MD, MPH

H. NCI Head and Neck Steering Committee update  Christine Chung, MD, PhD

QUESTIONS / DISCUSSION
I. Welcome

Presenter: Erich Sturgis, MD, MPH

II. Brief Updates:

A. The Drew Ridge NRG Head and Neck Surgical Subcommittee Travel Award

Summer 2022 Recipient - Linda X. Yin, MD; University of Michigan

Presenter: Erich Sturgis, MD, MPH

B. Announcements:

New HN Surgery Subcommittee Co-Chair - Chris Holsinger, MD
New Surgical Oncology Committee Chair - Stephen Lai, MD, PhD
New VA-MTF Subcommittee Chair - Vlad Sandulache, MD, PhD
Surgeons rotated off Core Committee - Drew Ridge, MD & Neil Gross, MD; & Kate Hutcheson, PhD
Surgeons selected for Core - Steven Chinn, MD; John De Almeida, MD; & Stephen Lai, MD, PhD

Presenter: Erich Sturgis, MD, MPH

III. Brief Updates of Open Trials (8:10 a.m.):

A. HN006 – Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer

Presenter: Steve Chang, MD

B. RTOG 1216 – Randomized Phase II/III Trial of Adj XRT with Cisplatin, Docetaxel-Cetuximab, or Cis-Atezolizumab in Path High-Risk SCCHN

Presenter: Paul Harari, MD

C. CCTG HN11 SELECT – SPECT-CT Guided Treatment of Contralateral Neck in Oropharyngeal Cancer

Presenter: John De Almeida

IV. New Trial Concepts and Trials in Development (8:40 a.m.):

A. SPARE Trial – Sparing pharyngeal radiotherapy with transoral lingual tonsillectomy vs Selective pharyngeal RT for p16 positive unknown primary SCC

Presenter: John De Almeida

B. HN2139 – Phase II Randomized Trial of Chemo Immunotherapy or Immunotherapy in Patients with Recurrent / Persistent PDL1 Enriched HNSCC Undergoing Salvage Surgery

Presenter: Nabil Saba, MD

IV. Early Investigators Experiences (9:10 a.m.):

A. HN2139 – Translational Studies

Presenters:

Steven Chinn, MD & Nikki Schmitt, MD

V. Adjourn (9:55 a.m.):

Presenter: Erich Sturgis, MD, MPH

A. Next Meeting – January 26-28, 2023; Orlando World Center Marriott; Orlando, FL
Agenda

12:00 pm - 12:10 pm  Welcome/Announcements – Jennifer Wenzel, PhD, RN, CCM, FAAN / Chanita Hughes Halbert, PhD

Research Spotlight - Victoria Bae-Jump, MD, PhD / Jennifer Wenzel, PhD, RN, CCM, FAAN

12:10 pm – 12:25 pm  NRG Oncology Health Equity New Investigator Mentor Program for Underrepresented Minority (URM) Scholars


12:25 pm – 12:45 pm  NCORP pilot project recipient

- Radhika Gogoi M.D., PhD - Relational Agents in HPV Vaccine Education

12:45 pm - 1:00 pm  Research Implementation (Education/Training/Mentorship) SIG update – Victoria Bae-Jump, MD, PhD / Mylin Torres, MD

Clinical Trial Enrollment Updates - Statistics/Metrics - SDMC Reports - Victoria Bae-Jump, MD, PhD / Reena Cecchini, PhD, MS

1:00 pm – 1:10 pm  Older Adult Research SIG update – William Tew, MD

1:10 pm – 1:20 pm  Rural Health Research SIG Update – Na Tosha Gatson, MD, PhD, FAAN / Shearwood McClelland, MD

1:20 pm – 1:35 pm  HDC Research Concept Development SIG update - Chanita Hughes Halbert, PhD / Evan Graboyes, MD, MPH, FACS

1:35 pm  Closing remarks/Summary/Adjournment

*Please note times listed are EASTERN TIME ZONE
IMAGING COMMITTEE MEETING

Meeting Link: Join through the NRG Oncology Meeting Dashboard

Date: Monday July 18, 2022
Start and End Time: 1:30 PM-3:30 PM Eastern/12:30 PM-2:30 PM Central/10:30 AM-12:30 PM Pacific
Chair: Daniel Pryma, MD
Vice Chair: Amy Fowler, MD, PhD
NRG Staff Support: Denise Manfredi, BS., R.T.(T)(ARRT)

MEETING AGENDA
(Eastern Times - PM)

1:30 – 1:35 Opening Remarks/Welcome
Amy Fowler

1:35 – 1:55 Imaging Disease Site Reports
- H&N: Cynthia Wu, MD / Min Yao, MD
- Brain: Tammy Benzinger, MD / Ashok Srinivasan, MD
- Breast: Heidi Umphrey, MD / Mohammad Eghtedari, MD
- Gyn: Karthik Sundaram, MD
- GI: Aoife Kilcoyne, MD
- GU: Ashesh Jani MD / Bill Hall, MD
- Lung: Michelle Ginsberg, MD
- Sarcoma: Dan Pryma, MD

1:55-2:10 Open Discussion
All

2:10-2:20 IROC PHL for NRG Oncology Trials Updates
Michael Boss, PhD

2:20- 2:30 RPT Trials Update
Ying Xiao, PhD / Michael Boss, PhD

IMAGING AND MEDICAL PHYSICS JOINT SYMPOSIUM

(Eastern Times - PM)

2:30 – 2:32 Introduction: Imaging and Medical Physics Joint Symposium
Dan Pryma/Ying Xiao
Theme: “Imaging for treatment response and toxicity assessment for Radiotherapy in Lung cancer”

2:32 – 3:00 An overview of Lung Cancer Radiotherapy including SBRT Patient Selection
Speaker: Stephen Chun, MD, Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

3:00 – 3:28 Overview of Lung Cancer Imaging after Radiotherapy
Speaker: Maya Galperin-Aizenberg, MD, Assistant Professor of Clinical Radiology, Hospital of the University of Pennsylvania

3:28 - 3:30 Closing Remarks
Dan Pryma / Amy Fowler

3:30pm Adjournment
# IMAGING AND MEDICAL PHYSICS JOINT SYMPOSIUM

**Zoom meeting Link:** Join through the NRG Oncology Meeting Dashboard

<table>
<thead>
<tr>
<th>Date:</th>
<th>Monday July 18, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start and End Time:</td>
<td>2:30 PM-3:30 PM Eastern</td>
</tr>
<tr>
<td>Moderators:</td>
<td>Daniel Pryma, MD / Ying Xiao, PhD</td>
</tr>
<tr>
<td>Co-Moderators</td>
<td>Amy Fowler, MD, PhD</td>
</tr>
</tbody>
</table>

*(Eastern Times - PM)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 2:30 – 2:32| **Introduction:** Imaging and Medical Physics Joint Symposium  
Theme: “Imaging for treatment response and toxicity assessment for Radiotherapy in Lung cancer”  
Dan Pryma/Ying Xiao |
| 2:32 – 3:00| **An overview of Lung Cancer Radiotherapy including SBRT Patient Selection**  
Speaker: Stephen Chun, MD, Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 3:00 – 3:28| **Overview of Lung Cancer Imaging after Radiotherapy**  
Speaker: Maya Galperin-Aizenberg, MD, Assistant Professor of Clinical Radiology, Hospital of the University of Pennsylvania |
| 3:28 - 3:30| ** Closing Remarks / Adjournment**  
Dan Pryma / Amy Fowler |
Lung Cancer General Meeting

Date: Saturday, July 23, 2022
Start and End time: 9:15 am – 11:00 am
Chair: Jeffrey Bradley, MD
Co-Chairs: Jessica Donington, MD PhD
Martin Edelman, MD

Learning Objectives:
Following this activity, participants will be better able to: a) learn about ongoing clinical trials within the lung cancer committee; b) participate in feedback about ongoing and prospective trials; and c) develop strategies to participate in these trials at your home institution.

Active Studies:

<table>
<thead>
<tr>
<th></th>
<th>Study ID</th>
<th>Description</th>
<th>Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>RTOG 1308</td>
<td>Protons vs photons for St III NSCLC</td>
<td>Xing Liao</td>
</tr>
<tr>
<td>B</td>
<td>NRG-LU002</td>
<td>Phase II/III chemo +/- SBRT for Stage IV</td>
<td>Puneeth Iyengar</td>
</tr>
<tr>
<td>C</td>
<td>NRG-LU004</td>
<td>Phase I anti-PD1 concurrent with RT</td>
<td>Steven Lin</td>
</tr>
<tr>
<td>D</td>
<td>NRG/Alliance-LU005</td>
<td>Phase III Limited-stage SCLC</td>
<td>Kristin Higgins</td>
</tr>
<tr>
<td>E</td>
<td>NRG-LU006</td>
<td>Phase III; Dose-painting IMRT for mesothelioma</td>
<td>Andreas Rimner</td>
</tr>
<tr>
<td>F</td>
<td>NRG-LU007</td>
<td>Phase II/III ES-SCLC; chemo+atezo +/- RT</td>
<td>Quynh-Nhu Nguyen</td>
</tr>
<tr>
<td>G</td>
<td>NRG-LU008</td>
<td>Phase III; SBRT+chemoRT for locally-advanced NSCLC</td>
<td>Charles Simone</td>
</tr>
<tr>
<td>H</td>
<td>SWOG S1914</td>
<td>Phase III SBRT +/- neoadjuvant atezo for Stage I</td>
<td>Charles Simone</td>
</tr>
<tr>
<td>I</td>
<td>RTOG 3515 / PAC 4</td>
<td>SBRT +/- durva for medically-inoperable Stage 1</td>
<td>Jeffrey Bradley</td>
</tr>
<tr>
<td>J</td>
<td>NRG-CC003</td>
<td>Hippocampal avoidance brain</td>
<td>Vinai Gondi</td>
</tr>
<tr>
<td>K</td>
<td>NRG-CC009</td>
<td>SRS vs HA-WBRT for SCLC brain mets</td>
<td>Vinai Gondi</td>
</tr>
<tr>
<td>L</td>
<td>Lung-MAP SWOG S-1400</td>
<td></td>
<td>Anjali Rohatgi</td>
</tr>
<tr>
<td>M</td>
<td>ALCHEMIST Trial</td>
<td></td>
<td>Anjali Rohatgi</td>
</tr>
<tr>
<td></td>
<td>Agenda Item</td>
<td>Presenter(s)</td>
<td>Duration</td>
</tr>
<tr>
<td>---</td>
<td>------------------------------------------------</td>
<td>------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>1</td>
<td>Intro/Committee Update</td>
<td>Jeff Bradley</td>
<td>10 min</td>
</tr>
<tr>
<td>2</td>
<td>NRG-LU2022 - Personalized targeted therapy for St III</td>
<td>Carl Gay (JBradley to present)</td>
<td>10 min</td>
</tr>
<tr>
<td>3</td>
<td>NeoAdj chemo-IO vs ChemoRT for resectable St III A</td>
<td>Raid Aljumaily</td>
<td>15 min</td>
</tr>
<tr>
<td>4</td>
<td>NRG-LU004 Amendment - PDL1 &gt;50%; IO + RT vs PACIFIC NRG-LU2130 new trial</td>
<td>S. Lin</td>
<td>15 min</td>
</tr>
<tr>
<td>5</td>
<td>Phase Ib/II pre-op RT+atezo with tiragolumab in NSCLC</td>
<td>S. Tian</td>
<td>15 min</td>
</tr>
<tr>
<td>6</td>
<td>De-intensified RT for unresectable Stage III</td>
<td>N. Ohri</td>
<td>15 min</td>
</tr>
<tr>
<td>7</td>
<td>Ultracentral early-stage lung cancer</td>
<td>J Varlotto</td>
<td>15 min</td>
</tr>
<tr>
<td>8</td>
<td>Functional Lung Avoidance idea (secondary endpoint?)</td>
<td>Andrew Baschnagel</td>
<td>15 min</td>
</tr>
</tbody>
</table>
Medical Oncology Committee Meeting Agenda

Date: Monday, July 18th, 2022
Start and End Time: 10:00 am – 12:00 pm
Chairs: Corey Langer, MD; Deborah Armstrong, MD

LEARNING OBJECTIVES
Following this activity, participants will be better able to:
1. Update disease-specific clinical trial outcomes and major advances from ASCO 2022 and other critical advances
2. Identify unique studies involving systemic therapy in the Medical Oncology sphere
3. Define and update the criteria for arms of the ComboMatch study
4. Itemize the accomplishments of the Pharmacy Subcommittee and its bearing on protocol conduct
5. Define the goals of the new Immunotherapy Subcommittee

WORKSHOP AGENDA

I. Introductions
   Corey Langer, MD
II. ComboMatch Update
    Roisin O’Cearbhaill, MD
III. Pharmacy Subcommittee Update
     Judith Smith, PharmD
IV. Immunotherapy Subcommittee Introduction
    Deborah Armstrong, MD
Susanna Ulahannan, MD
V. Disease Site Medical Oncology updates (10 min each):
   a. CNS
      Manmeet Ahluwalia, MD
   b. GYN
      Deborah Armstrong, MD
   c. HNC
      Jennifer Choe, MD
   d. Thoracic
      Corey Langer, MD
   e. GU
      Tanya Dorff, MD
   f. GI
      Mohammed Salem, MD
VI. Other business
    Corey Langer, MD; Deborah Armstrong, MD

DISCUSSION
Medical Physics Subcommittee Virtual Meeting Agenda
CENTER FOR INNOVATION IN RADIATION ONCOLOGY (CIRO)

Meeting Link: Obtain through the NRG Oncology Meeting Portal

Date: Monday July 18, 2022
Start and End Time: 3:30 PM - 5:00 PM (Eastern)
Chair: Ying Xiao, PhD
Vice Chair: Stanley Benedict, PhD
NRG Support: Elizabeth O’Meara and Theresa Powell, CAPM

IMAGING AND MEDICAL PHYSICS JOINT SYMPOSIUM

(Eastern Times - PM)
(Eastern Times - PM)

2:30 – 2:32 Introduction: Imaging and Medical Physics Joint Symposium
 Dan Pryma/Ying Xiao
 Theme: “Imaging for treatment response and toxicity assessment for Radiotherapy in Lung cancer”

2:32 – 3:00 An overview of Lung Cancer Radiotherapy including SBRT Patient Selection
 Speaker: Stephen Chun, MD, Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

3:00 – 3:28 Overview of Lung Cancer Imaging after Radiotherapy
 Speaker: Maya Galperin-Aizenberg, MD, Assistant Professor of Clinical Radiology, Hospital of the University of Pennsylvania

3:28 – 3:30 Closing Remarks
 Dan Pryma / Amy Fowler

3:30pm Adjournment

3:30 – 3:32 Introductions
 Ying Xiao, PhD
 • Subcommittee Updates
 Stanley Benedict, PhD

3:32 – 3:40 NCI/NCTN Updates
 Ceferino Obcemea, PhD
 • NCI Communications
 • NCTN Medical Physics

3:40 – 3:50 NRG QA Report
 • IROC Houston
   Stephen Kry, PhD
 • IROC Philadelphia RT (Contouring & Dosimetry)
   Ying Xiao, PhD
 • IROC Philadelphia Imaging (reporting at 2:45 pm)
   Mark Rosen, MD / Michael Boss, PhD

3:50 – 4:15 Disease Site Reports
 • Brain
   Yunfeng Cui, PhD / Fang-Fang Yin, PhD
 • Breast
   Guang-Pei Chen, PhD / Jean Moran, PhD
 • GI
   William Parker, M.Sc./ Gemma Davies, PhD
 • GU
   Rajat Kudchadker, PhD/Mihaela Rosu, PhD
 • GYN
   Hayeon Kim, PhD / Cecilia Lee, PhD
 • H&N
   Nataliya Kovalchuk, PhD / Ping Xia, PhD
 • Lung
   Martha Matuszak, PhD / Timothy Ritter, PhD
 • NCORP
   Yimei Huang, PhD / Tian Liu, PhD

4:15 – 4:25 Modality Technology Reports
 • Notable Technologies (Proton)
   Xiaoying Liang, PhD
   Proton SBRT
   Liyong Lin, PhD

4:25 – 4:58 Working Group and Other Updates
 • Recommendations and Guidelines for Clinical Trials involving Artificial Intelligence Assisted Automated Segmentation in Radiotherapy
   Sharon Qi, PhD / Yi Rong, PhD
 • RPT Dosimetry
   Jacek Capala, PhD
 • FLASH
   Jennifer Zou, PhD
 • SFRT
   Heng Li, PhD
 • Radiomics Phantom
   Jason Sohn, PhD

4:58 Other Business: Questions / Discussions

5:00 Adjournment
Ovarian Workshop Agenda

Date: Friday, July 22, 2022
Start and End Time: 1:15pm-3:45pm CDT
Chair: Kathleen Moore, MD, MS
Co-Chair: Joyce Liu, MD, MPH
Translational Chair: Elizabeth Swisher, MD
Translational Co-Chair: Rebecca Arend, MD

Learning Objectives:
Following this activity, participants will be better able to:
1. Review the status of completed and ongoing NRG/GOG clinical trials on the treatment of ovarian cancer
2. Review the status of approved NRG/GOG concepts that are under development
3. Apply standard and review procedures required to design, submit, and conduct a research protocol within NRG, including ancillary data proposals
4. Assure strict quality control of NRG/GOG clinical trials

WORKSHOP AGENDA
Note: The actual order of topics and discussion is subject to change, depending on availability of participants

A. Introduction
   • Review of learning objectives
   • Statements regarding potential conflicts of interest
   • Committee membership updates

B. ASCO Updates
   • GY007 presentation and discussion (Landen/Buckanovich)

C. Review of Closed Studies (not terminated)

<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOG-0212</td>
<td>A randomized phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single agent paclitaxel or CT-2103 (IND#70177) versus no treatment until documented relapse in women with advanced ovarian, primary peritoneal or fallopian tube cancer who achieve a complete clinical response to primary platinum/taxane chemotherapy (Larry J Copeland)</td>
<td>In press, JCO</td>
</tr>
<tr>
<td>GOG-0213</td>
<td>A phase III randomized controlled clinical trial of carboplatin and paclitaxel (or gemcitabine) alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian peritoneal primary and fallopian tube cancer (Robert Coleman)</td>
<td>Lancet Oncol 2017 NEJM 2019</td>
</tr>
<tr>
<td>GOG-0262</td>
<td>A randomized phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel in combination with carboplatin with or without concurrent and consolidation bevacizumab in the treatment of primary stage III or IV epithelial ovarian, peritoneal or fallopian tube cancer (John K Chan)</td>
<td>NEJM 2016</td>
</tr>
<tr>
<td>GOG-0273</td>
<td>Chemotherapy toxicity in elderly women with ovarian, primary peritoneal, or fallopian tube cancer (Vivian E von Gruenigen)</td>
<td>Modified dose dense cohort manuscript in draft form</td>
</tr>
<tr>
<td>NRG-GY003</td>
<td>Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (Zamarin)</td>
<td>J Clin Oncol 2020</td>
</tr>
<tr>
<td>GOG-0281</td>
<td>RP2/3 study to assess efficacy of Trametinib in recurrent or progressive low grade serous ovarian or peritoneal cancer. (David Gershenson)</td>
<td>Presented IGCS 2019 Lancet 2022</td>
</tr>
</tbody>
</table>
### Study Title Notes

<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOG-0264</td>
<td>RP2 trial paclitaxel-carboplatin vs BEP for newly diagnosed advanced-stage and recurrent chemo-naïve sex cord stromal tumors of the ovary (Jubilee Brown)</td>
<td>Presented IGCS 2020</td>
</tr>
<tr>
<td>NRG-GY004</td>
<td>Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Joyce Liu and Ursula Matulonis)</td>
<td>Presented ASCO 2020 J Clin Oncol 2022</td>
</tr>
</tbody>
</table>

### D. Review of Active Studies (all metrics are as of 6/2022)

<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG-GY005</td>
<td>A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Jung-Min Lee and Angeles Alvarez Secord)</td>
<td>Closed to accrual 10/02/2020 Total accrual 562</td>
</tr>
<tr>
<td>NRG-GY007</td>
<td>A Phase I/II Study of Ruxolitinib with Front-line Neoadjuvant and Post-surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary peritoneal Cancer. (Chip Landen)</td>
<td>Presented ASCO 2022</td>
</tr>
<tr>
<td>NRG-GY009</td>
<td>A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and Atezolizumab vs Pegylated Liposomal Doxorubicin/Bevacizumab and Atezolizumab vs Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer (Roisin O’Cearbhaill, Carol Aghajanian)</td>
<td>Closed to accrual 10/2021 Total accrual 444</td>
</tr>
<tr>
<td>NRG-GY014 (DT1718)</td>
<td>A Phase II study of tazemetostat (EPZ-64438), an EZH2 inhibitor, in select gynecologic cancers (NCI CRDL LOI request). Limited sample size (n = 31), but requires genomics screening. (Ramez Eskander and David Hyman)</td>
<td>Reopened 02/2022 to ARID1mt clear cell ovca Step 1 Registration Closed 06/2022</td>
</tr>
<tr>
<td>NRG-GY019 (RT1753)</td>
<td>A Phase III Randomized Three Arm trial of paclitaxel/carboplatin compared to paclitaxel/carboplatin/maintenance letrozole versus letrozole monotherapy in patients with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum. (Amanda Nickles-Fader)</td>
<td>Activated 8/26/19 163/450</td>
</tr>
<tr>
<td>NRG-GY021</td>
<td>Randomized Phase II Trial of olaparib + tremelimumab vs olaparib in platinum sensitive recurrent ovarian cancer/HRD+ and HRD. (Sarah Adams)</td>
<td>Closed to accrual 10/19/2020</td>
</tr>
<tr>
<td>NRG-GY023</td>
<td>A randomized phase II trial of triplet therapy (a PD-L1 inhibitor durvalumab in combination with olaparib and cediranib) vs. doublet therapy (olaparib and cediranib) vs doublet therapy (durvalumab and cediranib) vs physician choice chemotherapy in women with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal or fallopian cancer who have received prior bevacizumab (Jung-min Lee)</td>
<td>Activated 4/28/21 81/164</td>
</tr>
<tr>
<td>NRG-CC008 (CC1923) (NC1427) (CPC1206)</td>
<td>A non-randomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers (SOROCK) (Joan Walker)</td>
<td>Activated 6/2020 173/2262 Amendment pending to allow surgery by non-NCTN/NCORP surgeons</td>
</tr>
<tr>
<td>Study</td>
<td>Title</td>
<td>Notes</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>AGCT1531 (RT1205)</td>
<td>Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors (MaGIC, COG primary, Al Covens NRG)</td>
<td>Activated 5/2017 682/2059</td>
</tr>
</tbody>
</table>

**E. Review of Approved Concepts under Development**

<table>
<thead>
<tr>
<th>Concept</th>
<th>Title</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG-GY027</td>
<td>A Phase IB Trial of Ipatasertib plus paclitaxel and carboplatin in women undergoing neoadjuvant chemotherapy for treatment naive, epithelial ovarian cancer (Katherine Fuh/Kathleen Moore)</td>
<td>CIRB approved 6/6/22 Awaiting final activation</td>
</tr>
<tr>
<td>NRG-GY030</td>
<td>A Randomized Phase III Study of the ATR inhibitor Berzosertib in Combination with Gemcitabine versus Gemcitabine alone in Platinum Resistant/Refractory High Grade Serous Ovarian Cancer (HGSOC) (Panagiotis A. Konstantinopoulos MD, PhD)</td>
<td>EMD Serono not developing berzosertib further. Trial withdrawn 6/2022</td>
</tr>
<tr>
<td>PI1966</td>
<td>Wee1 + ATRi in CCNE1 amplified ovarian and endometrial (Simpkins)</td>
<td>Wee1i and ATRi options being explored</td>
</tr>
<tr>
<td>DT2106</td>
<td>A Phase IB study of combination BET protein inhibition (ZEN3694) and ATR kinase (M1774) for the treatment of recurrent ARID1A mutated clear cell and endometrioid ovarian carcinomas (Yasuto Kinose/Fiona Simpkins)</td>
<td>RSC 07/2021 LOI 11/22/21; AOH 12/22/21 Response to CTEP 2/10/22 LOI approved 6/21/22</td>
</tr>
<tr>
<td>OV2135</td>
<td>Randomized Phase II of Paclitaxel /Carboplatin/Bevacizumab +/-Selinexor in Ovarian, Tubal, Peritoneal Carcinoma characterized as homologous recombination proficient (HRp). (Arend/Rubinstein/Moore)</td>
<td>Disapproved by GCSC</td>
</tr>
<tr>
<td>PI2132</td>
<td>A Phase Ib/II Study of adavosertib combined with carboplatin in women with primary platinum-resistant TP53-mutated ovarian, fallopian tube, or primary peritoneal carcinoma with and without CCNE1 amplifications. (Washington/Naqash/Moore)</td>
<td>Concept withdrawn (drug availability)</td>
</tr>
<tr>
<td>PI2134</td>
<td>A Multi-Arm, Non-Comparative Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Carboplatin and Paclitaxel in Combination with ZEN003694, or Birinapant in Epithelial Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer. (Arend/Moore/Martin)</td>
<td>Concept withdrawn (drug availability) – may move forward new concept with tolinapant arm alone</td>
</tr>
</tbody>
</table>

**F. Updates on Returning Concepts**

<table>
<thead>
<tr>
<th>Concept</th>
<th>Title</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>OV2206</td>
<td>Randomized Phase 2/3 Trial of Weekly Paclitaxel with or without Birinapant for Platinum Resistant, Recurrent Epithelial Ovarian Cancer (Moore, Annunziata).</td>
<td>OTF 05/2022 Revision to tolinapant (drug availability) and will be re-reviewed</td>
</tr>
<tr>
<td>OV2209</td>
<td>Phase II Combination ATR and PARP Inhibitor following PARP inhibition in recurrent ovarian cancer: a comparison of PARPi and</td>
<td>Concept withdrawn</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Concept</td>
<td>Title</td>
<td>Notes</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>ATRI combination (olaparib and ceralasertib) and standard of care platinum doublet. (OV2109R) (Simpkins, Wethington)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

G. Review of New Concepts

H. CTEP/CRADA Review (Moore and Liu)

I. EDUCATIONAL TALK: Possibilities for Immune Therapy in Ovarian Cancer (Sarah Adams)

J. DISCUSSION: Elements of a successful LOI/Concept

- Hypothesis
- Statistical Design
- Endpoints

QUESTIONS/DISCUSSION
Learning Objective: (List at least 1 learning objective specific to the discussion)
1. Identify and describe the design and status of new and ongoing clinical being planned and conducted by NRG Oncology to optimize protocol design and patient enrollment.

2. Identify, describe, and discuss aspects of ongoing NRG Oncology clinical trials using proton therapy that are in need of special support and improvement to enable effective patient enrollment in and treatment on these trials.

Workshop Agenda
6:45 - 6:55 am Welcome Address / Chair Report Charles Simimone
6:55 – 7:00 am Update from NCI Jeff Buchsbaum/Ceferino Obcemea
7:00 – 7:05 am Update on Proton Center Credentialing by IROC Houston Jessica Lowenstein
7:05 – 7:10 am Update on Medical Physics Proton Ying Xiao

Protocol(s) / Concept(s) Update from Members
7:10 – 7:20 am GU Studies Jason Efstathiou
• NRG-GU008
• NRG-GU009
• NRG-GU010

7:20 – 7:25 am COMPARE Prostate Study Nancy Mendenhall

7:25 – 7:35 am GI Studies Ted Hong
• NRG-GI003
• NRG-GI006
Saumil Gandhi

7:35 – 7:45 am Brain Studies Vinai Gondi
• NRG-BN001
• NRG-BN003
• NRG-BN005

7:45 – 7:55 am Lung Studies Charles Simone
• NRG/RTOG 1308
• NRG-LU006
• NRG-LU008

7:55 – 8:00 am H & N Studies Nancy Lee
• NRG-HN001

8:00 – 8:05 am RADCOMP Breast Study Isabelle Choi
• RTOG 3509/3510

8:05 – 8:15 am Question/Discussion Adjournment C. Simone, MD
Pathology Workshop Agenda

Date: Monday, July 25, 2022
Start and End Time: 1:00pm - 3:00pm CT

Chair: Jeffry Simko, MD, PhD
Co-Chairs: Peter Lucas, MD, PhD / Tan Ince, MD, PhD

Learning Objectives:
Following this activity, participants will be better able:

1. To understand new technologies that can expand and extend the value of biospecimens for clinical use, patient management, and research applications.
2. To understand the utility, routes of access, and use of biospecimens in cooperative group research efforts.
3. To understand how pathologists can and are participating in the support of NRG clinical trial activities.

WORKSHOP AGENDA

“FIBI Slide-Free Microscopy for Simple, Rapid, Non-Destructive Tissue Diagnostics: Core Needles and Margins”
Richard Levenson, MD (UC Davis Health System)

“Committee Updates”
Jeffry Simko, MD, PhD (University of California, San Francisco) Peter Lucas, MD, PhD (University of Pittsburgh) Tan Ince, MD, PhD (Weill Cornell Medicine)

“Disease Site Pathology Reports”
Disease Site Pathologists

QUESTIONS / DISCUSSION
Patient Centered Outcomes Research (PCOR) Workshop Agenda

Date: Thursday, July 21, 2022
Start and End Time: 2:00 pm – 3:30 pm (CDT)
Co-Chairs: Ben Movsas, MD; Patricia Ganz, MD; Lari Wenzel, PhD

Learning Objectives:
Following this activity, participants will be better able to:

1. Understand the importance of QOL compliance and data completeness
2. Analyze appropriate PRO and CER endpoints and instruments for use in NCTN Phase II and III clinical trials
3. Apply criteria for inclusion of PROs, CER, and PRO-CTCAE in NCTN Phase II and III clinical trials

Session Introduction and Welcome
Ben Movsas, MD

2:00 – 2:05
2:05 – 2:40 Perspectives on Quality of Life and Patient-Reported Outcomes in Gynecologic Oncology: Influence on Future Directions
Lari Wenzel, PhD

2:40 – 2:50 PRO and QOL Data Compliance Update
Marcie Ritter, PhD
Kandie Dempsey, DBA, MS, RN, OCN

2:50 – 3:20 Developing Concepts/Protocols

NRG-LU008: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
Nitin Ohri, MD

Pulsed RT (TMPRT) for Elderly GBM
Jiayi Huang, MD

3:20 – 3:30 Closing Remarks
Ben Movsas, MD
Patricia Ganz, MD
Lari Wenzel, PhD
Pharmacy Subcommittee Meeting Agenda

Date: Tuesday, July 19, 2022
Start and End Time: 1:30 PM – 3:00PM (EDT)
Chair: Judith Smith, B.S., Pharm.D., BCOP, CPHQ

Learning Objectives:
Following this activity, participants will be better able to:

1. Discuss the supportive care resources available to investigators for management of common toxicities associated with chemotherapy.
2. Recognize the benefits of pharmacy review on NRG Oncology research protocols
3. Understand the rationale and benefits of standardizing drug information for research protocols.
4. Discuss the challenges in the management of cellular therapies in patients with solid tumors.
5. Understand the protocol requirements to allow use of biosimilars on clinical trials.

AGENDA

I. Introductions (5 minutes)

II. CME lecture: "Challenges of Cellular Therapy in Patients with Solid Tumors"
Roisin O’Cearbhaill, M.D. (20 min)

III. NRG committee Pharmacy Liaison Assignments & Updates - Judith Smith, Pharm.D. (5 min)

IV. Practice Recommendation Documents – ALL (25 min)
   a. Discussion on dose rounding statement proposal
   b. Other resources to be developed:
      i. Chemotherapy with Photosensitivity- David DeRemer, Pharm.D.
      ii. Monitoring Drug/Drug Interactions - David DeRemer, Pharm.D.
      iii. Guidelines for reducing PARP inhibitor toxicities – Judith Smith- Pharm.D.

V. Biosimilars Update - Judith Smith, Pharm.D. (15 min)
   a. Protocol verbiage

VI. Collaboration with Pharmacy Committees in other Cooperative Groups – Judith Smith (5 min)

VII. PMB Updates – Kayla Dye, Pharm.D.(10 min)

VIII. Other Discussion Items (10 min) - All
Protocol Support Committee
Clinical Trial Nurse/Clinical Research Associate Continuing Educational Sessions

Date: Thursday, July 21, 2022
Start and End Time: 8:00 am CT - 1:00 pm CT
PSC Chair: Terry Thomas MS, CCRC
PSC Vice Chairs: Nancy Fusco RN, BSN, CCRP & Cynthia Licavoli RN, BSN, MA
Program Facilitator: Cynthia Licavoli RN, BSN, MA & Lauren Seames, MPH, CCRC
Format: Hybrid

Learning Objectives
Following this activity, participants will be better able to:
1. Discuss results of the Site CRP Survey, identifying greatest challenges for sites with possible solutions.
2. Discuss the evolving treatment options for colorectal cancer.
3. Describe the role that clinical trials perform in advancing the field of colorectal cancer management.
4. Describe precision medicine and identify appropriate testing and how to apply to treatment decisions.
5. Explain and identify current procedures and common trends for NCI-mandated Quality Assurance Audits.
6. Identify and discuss the key components of Patient Report Outcomes (PRO) compliance.
7. Discuss, locate, and describe current procedures and support services available with CTSU.
8. Identify Forte site materials for patient recruitment.
9. Discuss implementation of Forte site materials for patient recruitment.
10. Define the opportunities for addressing cancer health disparities through interventions using virtual technology.
11. Describe how patient preferences and needs can be incorporated to ensure a culturally appropriate intervention.

AGENDA

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am-8:10am</td>
<td>Introduction</td>
<td>Cynthia Licavoli RN, BSN, MA &amp; Lauren Seames MPH, CCRC</td>
</tr>
<tr>
<td>8:10am-8:20am</td>
<td>Welcome</td>
<td>Sharon Hartson Stine</td>
</tr>
<tr>
<td>8:20 am- 8:40 am</td>
<td>CRP Site Survey Results- Research Operations Initiative</td>
<td>Jennifer Dill, BS, CCRP</td>
</tr>
<tr>
<td>8:40 am- 9:35 am</td>
<td>Review of Colorectal Cancer 101</td>
<td>Thom George, MD</td>
</tr>
<tr>
<td>9:35 am - 10:10 am</td>
<td>Precision Medicine</td>
<td>Mary Walters, PharmD, BCOP</td>
</tr>
<tr>
<td>10:10am - 10:25am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:25 am- 10:45 am</td>
<td>Quality Assurance Program Updates</td>
<td>Mary Jo Antonelli, MBA, BS</td>
</tr>
<tr>
<td>10:45 am -11:05 am</td>
<td>Patient Reported Outcomes (PRO) Compliance</td>
<td>Marcie Ritter, PhD &amp; Kandie Dempsey, DBA, MS, RN, OCN</td>
</tr>
<tr>
<td>11:05 am- 11:30 am</td>
<td>CTSU Updates</td>
<td>Caroline Porter</td>
</tr>
<tr>
<td>11:30 am-11:45 am</td>
<td>FORTE</td>
<td>Cheryl Leow, MA</td>
</tr>
<tr>
<td>11:45 am-12:05 pm</td>
<td>Break &amp; Lunch Pick Up</td>
<td></td>
</tr>
<tr>
<td>12:05pm-12:10pm</td>
<td>Introduction</td>
<td>Cynthia Licavoli, RN, BSN, MA</td>
</tr>
<tr>
<td>12:10 pm – 1:00 pm</td>
<td>Virtual Human Technology</td>
<td>Eric Cooks, Ph.D. &amp; Andrew Maxim, M.Eng.</td>
</tr>
</tbody>
</table>
Learning Objectives
Following this activity, participants will be better able to:

1. Describe how the information obtained during roundtable discussions will impact the work process at your institution.
2. Identify how the best practices from the experts will improve quality of protocol reporting.
3. Explain how utilizing resources from the experts at NRG Oncology will improve conducting clinical trials.

Roundtable Discussions: 20-minute rounds every 25 minutes providing 8 sessions for participants
**Note: Refer to onsite handout provided to attendees, not all topics will be offered each session**

AGENDA

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. PSC HELP DESK</td>
<td>Joan Cahill, BSN, RN, OCN, CCRP</td>
</tr>
<tr>
<td></td>
<td>Becky Kramer, RN, BSN, CCRC</td>
</tr>
<tr>
<td></td>
<td>Nancy Fusco, RN, BSN, CCRP</td>
</tr>
<tr>
<td>2. Breast (BR007)</td>
<td>Mary Pat Matisko, RN, BSN</td>
</tr>
<tr>
<td>3. Colorectal (GI004, GI005, GI008)</td>
<td>Mary Pat Matisko, RN, BSN</td>
</tr>
<tr>
<td></td>
<td>Pamela Harris</td>
</tr>
<tr>
<td>4. GI FORTE (CC005)</td>
<td>Kristen Kotsko, RN, BSN</td>
</tr>
<tr>
<td></td>
<td>Izabela Frak</td>
</tr>
<tr>
<td></td>
<td>Cheryl Leow, MA</td>
</tr>
<tr>
<td>5. GYN Protocols</td>
<td>Lisa Barry, MEd, CCRP</td>
</tr>
<tr>
<td>6. Patient Reported Outcomes (PRO) Compliance</td>
<td>Marcie Ritter, PhD</td>
</tr>
<tr>
<td></td>
<td>Kandie Dempsey, DBA, MS, RN, OCN</td>
</tr>
<tr>
<td>7. NRG Oncology Quality Assurance Program</td>
<td>Mary Jo Antonelli, MBA, BS</td>
</tr>
<tr>
<td></td>
<td>Sally Bialy, MA</td>
</tr>
<tr>
<td>8. NRG Oncology Consents</td>
<td>Judy Langer, BS</td>
</tr>
</tbody>
</table>
9. NRG Oncology Membership/Payments
   Amy Niccolai, Wendy Michalow, Rylan Romesberg & Karan Boparai

10. NRG Oncology Communications
    Michelle Shepard
    Angie Pier

11. Adverse Event Reporting
    Sara McCartney, MS, RN

12. Neurocognitive Testing
    Catherine Sullaway, MS

13. IROC Radiation Therapy
    Jessica Lowenstein, MS, DABR

14. IROC Diagnostic Imaging
    Michael Boss, PhD

15. Vision Tree
    Sheena Gagh
    Mackenzie Kerwin

16. CTSU
    Caroline Porter

17. Best Practice: Organizing Your Workday: Part 1
    Cynthia Licavoli, RN, BSN, MA
    Maria Foschesato, RN, BSN

18. Best Practice: Organizing Your Workday: Part 2
    Tiffany Elsea, BA, CCRP
    Becky Kramer, RN, BSN, CCRC
    Alex Kudryashev MS, CCRP
    Marissa Weiss, MBA

    Terry Thomas, MS, CCRC
    Joni Short, RN, BSN, CCRC

20. Best Practice: Site Administrator
    Alison Ivey, RN, MS, MBA, OCN, CCRP
    Donna White, RN, BSN, OCN

    Stacey Lewis, BSN, RN, OCN
    Laura Sorci, BS, CCRP
    Michele Harmon, RN, BSN
    Michelle Meyers, RN, BSN, OCN
Protocol Support Committee (PSC)  
Education & Training Working Group (CLOSED)

Date: Thursday, July 21, 2022  
Start and End Time: 5:00 pm – 6:30 pm CT  
PSC Chair: Terry Thomas MS, CCRC  
PSC Vice Chairs: Nancy Fusco RN, BSN, CCRP & Cynthia Licavoli RN, BSN, MA  
Working Group Facilitator: Cynthia Licavoli, RN, BSN, MA  
Working Group Co-Facilitator: Lauren Seames, MPH, CCRC  
Room: ___________________ (Onsite only)

AGENDA:

1. Welcome & Introductions  
2. Review E&T Goals & Objectives  
3. Review meeting programing  
   a. Discuss morning hybrid offering  
   b. Discuss afternoon roundtable sessions  
4. Review and update list for potential continuing education session topics  
5. Discuss plans for winter 2023  
   a. Assign sub working group  
6. Discuss plans for summer 2023  
   a. Assign sub working group  
7. Discuss plans for future zoom calls between meetings  
8. Other business
Protocol Support Committee (PSC)
Mentor Working Group (CLOSED)

Date: Thursday, July 21, 2022
Start and End Time: 5:00 pm – 6:30 pm CT
PSC Chair: Terry Thomas MS, CCRC
PSC Vice Chairs: Nancy Fusco RN, BSN, CCRP & Cynthia Licavoli RN, BSN, MA
Working Group Facilitator: Nancy Fusco RN, BSN, CCRP
Working Group Co-Facilitator: Joni Shortt RN, BSN, CCRC
Room: ___________________ (hybrid for WG members)

AGENDA:

Joint meeting with mentors:
1. Roll call of Mentorship Working Group members and mentors
2. Approval of minutes from most recent mentor conference call: N/A. See WG minutes.
3. Announcements:
   a. Free professional head shots/group picture
   b. Retirements
   c. Upcoming vacancies: Co-Facilitator and Lead Mentor
4. Meeting guests
   a. Mary Jo Antonelli, Director, Quality Assurance and Operational Support
   b. Kandi Dempsey/Marcie Ritter, NRG Oncology PRO Data Compliance Officers
5. Mentor Reports: Recent contacts. Questions from WG.
6. Evaluation updates:
   a. Mentors
   b. Mentees

Working Group business meeting:
7. Approval of minutes from most recent WG conference call: 6/9/22
8. Recruiting mentors:
9. Recruiting WG members
10. Review ongoing projects for the working group:
   a. Introductory Materials for NRG Oncology Research Clinical Trials Coordinators:
      i. Number of website views: Review of data
      ii. Annual review: Mentors: January/February
      iii. PSC mailbox for FAQ section: Annually: Assignments to identify themes or new topics for Introductory Materials
      iv. Discuss new topics: RECIST Criteria Tool kit, Locating Patient Surveys, Steps to RT credentialing
   b. Mentor working group documents:
      i. Essential documents review: Standard Guidelines, Program Description, Mentor Request Form
   c. Mentor Program:
      i. Mentor/Mentee evaluations:
      ii. Mentor Conference Call Reports: N/A
      iii. Mentor engagement: PSC mailbox, Introductory Materials annual review, WG meetings, Mentor meetings
      iv. Mentee engagement: Evaluations, new ideas
      v. Audit Team and Quality Assurance and Communications WG engagement:
      vi. Development of Mentorship Program tools:
      vii. New items identified for the program:
   d. Future Projects: identified by items vi and vii
11. Meeting Plan: Monthly conference calls and WG meetings at NRG Oncology Semi-Annual Business Meeting
Date: Thursday, July 21, 2022
Start and End Time: 5:00 pm – 6:30 pm CT
PSC Chair: Terry Thomas MS, CCRC
PSC Vice Chairs: Nancy Fusco RN, BSN, CCRP & Cynthia Licavoli RN, BSN, MA
Working Group Facilitator: Terry Thomas MS, CCRC
Working Group Co-Facilitator: Tiffany Elsea, BA, CCRP
Room: ______________________ (hybrid for WG members)

AGENDA:

1. Introduction/Reintroduction of Working Group Members
   a. Roster Approval
   b. Resignations: Denise Luppe, Melissa Lynn, Spencer Coy, Jennifer Petrask
2. Discuss current Protocol review process.
   a. Review tracker
3. Update on Protocol Standards for inclusion vs exclusion
4. Update from the Protocol Development team
5. CIRB update – at last meeting International update
6. CTSU update
7. Other business
Protocol Support Committee (PSC)
Quality Control & Communication Working Group (CLOSED)

Date: Thursday, July 21, 2022
Start and End Time: 5:00 pm – 6:30 pm CT
PSC Chair: Terry Thomas MS, CCRC
PSC Vice Chairs: Nancy Fusco RN, BSN, CCRP & Cynthia Licavoli RN, BSN, MA
Working Group Facilitator: Donna White RN, BSN, OCN
Room: ______________ (hybrid for WG members)

AGENDA:

1. Introductions/Welcome
2. Review and approval of minutes from March 2022 meeting
3. Review/revise QC & Communication WG Goals and Objectives
4. Common Audit Findings: Mary Jo
   a. Suggestions for new projects based on above
5. Newsletter article discussion: review of planned articles
   a. Volunteer to write up meeting wrap up article for August
   b. Topic suggestions for future articles
6. Kandie Dempsey, NRG Oncology PRO Data Compliance Officer: PRO compliance
7. Communication and Website responsibilities
8. Co-Facilitator position interest
9. Next Meeting/call: best day/times
10. Other
Date: Saturday, July 23, 2022
Start and End Time: 7:00 am – 9:30 am CT
PSC Chair: Terry Thomas MS, CCRC
PSC Vice Chairs: Nancy Fusco RN, BSN, CCRP & Cynthia Licavoli RN, BSN, MA
Room: ______________________ (Onsite only)

AGENDA:

1. Meeting summary
2. Leadership Transition update and Introduction of new Members
3. Report from CTN and CRA Subcommittees- Alex Kudryashev and Alison Ivey (includes reports for Working Groups)
4. NRG Oncology Newsletter
5. NRG Oncology Committee reports
6. PSC representation on NRG Oncology committees - review
7. New Business
Radiation Oncology Committee Workshop Agenda

CENTER OF INNOVATION IN RADIATION ONCOLOGY (CIRO)

HYBRID LINK INFO TO BE ADDED

Date: Friday, July 22, 2022
Start and End Time: 8:00 am - 10:00 am CST in-person/9am-11am EST/6am-8am PST/7am-9am MST
Chair: Jeff Michalski, MD
Co-Chairs: Ivy Petersen, MD and Evan Wuthrick, MD

Learning Objectives
Following this activity, participant will be better able to:

1. Provide information on the latest developments related to the Imaging and Radiation Oncology Core (IROC) Group and NRG Oncology. Learn about mechanisms of quality assurance and protocol development as they relate to innovative technology in radiation oncology.
2. Describe different aspects of the field of medical physics such as credentialing for advanced technologies.
3. Discuss the most recent findings and technological advances in radiation oncology for multiple NRG clinical disease sites.

WORKSHOP AGENDA

8:00 – 8:05 Welcome / Introduction
     Evan Wuthrick, MD

8:05 – 8:15 NCI/NCTN Updates
     Ceferino Obcema, PhD
     • NCI Communications
     • NCTN Medical Physics

8:15 – 8:20 NRG RO Medical Physics Subcommittee Updates
     Ying Xiao, PhD / Stan Benedict, PhD

8:20 – 8:25 NRG RO Particle Therapy Workgroup Updates
     Charles Simone, MD

8:25 – 8:30 Imaging Committee
     Dan Pryma, MD

8:30 – 8:45 Imaging and Radiation Oncology Core (IROC)
     • IROC Houston
     • IROC Philadelphia
     • IROC (Contouring & Dosimetry)
       o Ying Xiao, PhD

8:45 – 9:49 Disease Site Reports – (Updates on concepts near development) (8mins)
     a. H&N
        Jimmy Caudell, MD / Jason Chan
        Christina Tsien, MD / Tony Wang, MD
     b. Brain
        Steven Chmura, MD / Simona Shaitelman, MD
        Eric Donnelly, MD / Mark Bernard, MD
     c. Breast
        Evan Wuthrick, MD / Emma Holliday, MD
     d. Gyn
        Dan Krauss, MD / Hiram Gay, MD
        Stephen Chun MD / Pamela Samson, MD
     e. GI
        Philip Wong, MD / Dian Wang, MD

9:49 – 10:00 Questions /Discussions

10:00 Adjournment
Rare Tumor Workshop Agenda

Date: Thursday, July 21, 2022
Start and End Time: 2:00 pm – 4:00 pm
Chair: Allen Covens, MD
Co-Chair: Jubilee Brown, MD

Learning Objectives:
Following this activity, participants will be better able to:

1. Discuss past, ongoing, and emerging NRG clinical trials in rare gynecologic cancers
2. Discuss priorities and promising preclinical and translational objectives for future clinical trials
3. Discuss outcome from preclinical workshop and strategies to increase the portfolio of clinical trials in rare gynecologic cancers
4. Discuss potential new collaboration with SGO Research Initiatives
5. Discuss new amendments to AGCT 1531 and strategies to disseminate and increase accrual

WORKSHOP AGENDA

Session I

A. Active Studies

1. AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors COG lead group. To date, this trial has accrued /2059 patients.

2. Gy019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum recently opened. Accrued xx/450.

3. GOG3026: Phase II trial of letrozole + Ribociclib for women with recurrent low-grade serous carcinoma. accrued x/50, second stage of accrual open.

4. GOG3051: A Phase II, Open Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumours. patients accrued xx

5. GOG3052: A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation. Accrued xx/100.

B. Previously proposed Studies

A091903: A Randomized Phase II Trial Of Adjuvant Nivolumab With Or Without Cabozantinib In Patients With Mucosal Melanoma. (Vicus). Opening imminently. CCTG participating.

RT2141: Phase II Study of Combination of Androgen Receptor (AR) Inhibition by Bicalutamide in combination with Leuprolide Acetate and Exemestane in Recurrent AR Positive Adult-Type Ovarian Granulosa Cell Tumor (Hopp) – approved by IDB 1/19/22. Approved RSC May/22
C. New Concepts

D. Closed Studies

0187, 0239, 0241, 0251, 0254, 0268, 0283, GY-001, 0281, 0264, Gy016

E. Other Business

1. Amendments to AGCT1531
## SARCOMA WORKING GROUP AGENDA

**Date:** Friday, July 22, 2022  
**Time:** 10:00 am – 12:00 pm CST  
**Location:** NRG Summer Meeting - Chicago, IL  
**Chair:** Dian Wang, MD, PhD  
**TRP Liaison:** Peter Houghton, PhD

<table>
<thead>
<tr>
<th>Section</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WELCOME</strong></td>
<td>Treena Davis-Trotman, NRG Senior Clinical Project Manager</td>
</tr>
<tr>
<td><strong>INTRODUCTIONS</strong></td>
<td>Dian Wang, MD, PhD</td>
</tr>
<tr>
<td><strong>ACTIVE STUDIES</strong></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>Phase Ib Study to Evaluate Neoadjuvant p53/MDM2 Inhibitor Combined with IMRT for Soft Tissue Sarcomas: <strong>UPDATE</strong></td>
</tr>
<tr>
<td></td>
<td>Meng Welliver, MD, PhD</td>
</tr>
<tr>
<td>2.</td>
<td>MGH/NRG: Phase I/II Trial of Preoperative Intensity Modulated Radiation Therapy (IMRT) for Retroperitoneal Sarcoma Using A Simultaneous Integrated Boost: <strong>UPDATE</strong></td>
</tr>
<tr>
<td></td>
<td>Yen-Lin Evelyn Chen, MD</td>
</tr>
<tr>
<td>3.</td>
<td>Registry to Evaluate the Safety and Feasibility of Treating Retroperitoneal Sarcomas with Permanently Implantable LDR CivaSheet (Howell/Wang): <strong>ON HOLD</strong></td>
</tr>
<tr>
<td><strong>NEW CONCEPTS</strong></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>Phase Ib Study on Breast Angiosarcoma Treated with ChemoRT TKI +/- IO Followed by Surgery: <strong>UPDATE</strong></td>
</tr>
<tr>
<td></td>
<td>Parul Barry, MD</td>
</tr>
<tr>
<td>2.</td>
<td>Short Course vs Long Course Radiation for Resectable, High-grade Soft-tissue Sarcoma of the Extremity (Harris): <strong>ON HOLD</strong></td>
</tr>
</tbody>
</table>

NRG Oncology Meeting - July 2022
## DEVELOPING CONCEPTS

1. Phase II Trial of Grid Sarcoma (JW Snider, Majid Mohiuddin and Rob Griffin): **ON HOLD**
2. Phase II Checkpoint Inhibitor with Low dose and High dose RT (RadScopal) Trial of Soft Tissue Sarcoma Pulmonary Metastases (Phil Wong): **ON HOLD**
4. AOST1921 (COG study concept): Pembrolizumab in Combination with Stereotactic Body Radiation Therapy (SBRT) and Surgery in Patients with Pulmonary Recurrence of Osteosarcoma (Thomas Cash): **ON HOLD**
5. Phase II Trial to Investigate the Role of Peri-operative RT in Desmoid Tumors Harboring CTNNB1 S45 Mutation (Pollock/Welliver): **ON HOLD**

## SARCOMA TRP

1. Synergistic effect of PARP inhibitor and radiation on soft tissue sarcoma
   - Meng Welliver, MD, PhD
2. Combining Talazoparib with RT in Ewing Sarcoma Xenograft Models
   - Peter Houghton, PhD

## NEW BUSINESS

ALL
Translational Science Agenda

Date: Thursday, July 21, 2022
Start and End Time: 4:00pm-6:00pm Central
Chairs: Michael Birrer, MD, PhD
Co-Chairs: Adam Dicker, MD, PhD ~ Vered Stearns, MD

Learning Objectives:
Following this activity, participants will be better able to:

1. To understand the role of AI in breast cancer research.
2. To understand the role of ctDNA in breast cancer.
3. To understand tumor heterogeneity in breast cancer.
4. To understand the translational science research in NRG Oncology trials.

WORKSHOP AGENDA

“Clinical Utility of ctDNA for Breast Cancer: The Breast is Yet to Come”
Ben Ho Park, MD, PhD (Vanderbilt University Medical Center)

“Rethinking Breast Cancer Risk Modeling with AI”
Prof. Regina Barzilay (MIT Computer Science & Artificial Intelligence Lab)

“Influence of African Ancestry on Tumor Biology”
Melissa Boneta Davis, PhD (Weill Cornell Medicine)

QUESTIONS / DISCUSSION
Translational Science Brain Cancer Subcommittee and Low Grade Glioma Working Group

Friday, July 22, 2022
4:30pm – 6:30pm CDT
Hyatt Regency ~ Chicago, Illinois

4:30 – 4:35
Introduction
(Arnab Chakravarti, MD)

4:35 – 4:50
“Methylation Profiling: A Critical Tool for Diagnosis and Classification in CNS Tumor Clinical Trials”
Kenneth Aldape, MD (National Institute of Health, (NIH))

4:50 – 5:05
“Image-Based Phenotyping of Glioblastomas for Clinical Use”
Aline Becker, MD, PhD (The Ohio State University (OSU))

5:05 – 5:20
"Biomarker Directed Methylation Classification for Gliomas"
Erik Sulman MD, PhD (New York University (NYU))

5:20 – 5:35
“Translational Research Updates on NRG Oncology/RTOG 0424, 9813, and 0825”
Jessica Fleming PhD (The Ohio State University (OSU))

5:35 – 5:50
“Haploinsufficiency of NFKBIA Reshapes the Epigenome and Imparts Disease Fate in Diffuse Gliomas"
Markus Bredel MD, PhD (University of Alabama (UAB))

5:50 – 6:05
“Understanding of Low-Grade Glioma Biology through Reconstructing Chromosome Structures from Hi-C Data”
Wei Meng, PhD (The Ohio State University (OSU))

6:05 – 6:30
Round Table Discussion
Translational Science GU Cancer Subcommittee Agenda

Date: Friday, July 22, 2022
Time: 4:30pm – 6:00pm CDT
Chairs: Phuoc Tran, MD, PhD

4:30 – 4:35 Introduction and Welcome
Phuoc Tran, MD, PhD (University of Maryland)

4:35 – 5:05 “Risk Reclassification in Prostate Cancer Patients via Digital Histopathology Multi-Modal Deep Learning Models in NRG Oncology Phase III Clinical Trials”
Jonathan Tward, MD, PhD (University of Utah)

5:05 – 5:35 “PCF Challenge Proposal - Germline Influence on Prostate Cancer Metastasis and Treatment Response”
Tyler Seibert, MD, PhD (University of California, San Diego)

5:35 – 5:55 "TS016 - NRG 0815 Decipher Validation"
Angela Jia, MD, PhD (Johns Hopkins University Hospital)

5:55 – 6:00 General TS Project Updates & Closing Remarks
Phuoc Tran, MD, PhD
Translational Science GYN Workshop Agenda

Date: Friday, July 22, 2022
Start and End Time: 4:30 am – 6:00 pm (Central Time)
Chair: Michael Birrer, MD, PhD
Co-Chair: Heather Lankes, PhD, MPH

Learning Objectives: To better understand the GYN translational science efforts of NRG Oncology. Following this activity, participants will be better able to:

1. Understand GYN translational science conducted by NRG and discuss GYN translational science projects.
2. Understand the organization and operations of the NRG Biospecimen Banks.
3. Understand the NRG biospecimen access process.
4. Assure strict quality control of NRG clinical trials, including GYN translational science.

WORKSHOP AGENDA

4:30-4:40 Opening Remarks
   Michael Birrer, MD, PhD
   Heather Lankes, PhD, MPH

GYN Subcommittee Translational Science Updates

4:40-4:50 Uterine Corpus Cancer Subcommittee
   Vickie Bae-Jump, MD, PhD
   Katherine Fuh, MD, PhD

4:50-5:05 Cervix/Vulva Cancer Subcommittee
   Dmitriy Zamarin, MD, PhD

5:05-5:15 Ovarian Cancer Subcommittee
   Rebecca Arend, MD

Rare Tumor Subcommittee
   Gloria Huang, MD

5:15-5:25 GYN Developmental Therapeutics
   Panagiotis Konstantinopoulos, MD, PhD

MP2PRT Moonshot Updates

5:25-5:40 Genomic and molecular characterization of biomarkers associated with self-reported race/ethnicity in high-risk endometrial cancers from NRG Oncology/GOG Protocol 210, Molecular Staging of Endometrial Cancer
   Casey Cosgrove, MD

5:40-5:55 Genomic and molecular characterization of biomarkers associated with tumor angiogenesis, DNA repair, and immunologic tolerance among exceptional responders and long-term survivors in NRG Oncology/Gynecologic Oncology Group protocol 240, a phase 3, randomized, controlled, open-label, multi-institutional, international trial of chemotherapy doublets with and without bevacizumab for primary treatment of women with recurrent, persistent, and/or metastatic cervical cancer (NCT00803062)
   Krish Tewari, MD

5:55-6:00 Closing Remarks
   Michael Birrer, MD, PhD
   Heather Lankes, PhD, MPH
Translational Science Head & Neck Cancer Subcommittee Agenda

Date: Friday, July 22, 2022
Time: 2:00pm – 3:00pm CST
Chairs: Neil Hayes, MD, PhD

2:00 – 2:05 Introduction and Welcome
Neil Hayes, MD, PhD (University of Tennessee)

2:05 – 2:30 “Hybrid EM in Head and Neck Cancer: Leading Edge Biology and Cross Talk with the Tumor Ecosystem”
Sid Puram, MD, PhD (Washington University in St. Louis)

2:30 – 2:55 “EAp53 as a predictive biomarker in HNSCC”
Curtis Pickering, PhD (MD Anderson Cancer Center)

2:55 – 3:00 Closing Remarks and Discussion
Neil Hayes, MD, PhD
## Translational Science LU Cancer Subcommittee Agenda

**Date:** Monday, July 18, 2022  
**Time:** 11:00am-1:00pm EST  
**Chair:** Bo Lu, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:05</td>
<td>Introduction and Welcome</td>
<td>Bo Lu, MD, PhD (Thomas Jefferson University)</td>
</tr>
<tr>
<td>11:05 – 11:30</td>
<td>“Crafting New Keys to Cure Lung Cancer: Developing Novel Combinations and Strategies in the Immunotherapy Era”</td>
<td>Andrew Song, MD (Merck &amp; Co., Inc.)</td>
</tr>
<tr>
<td>11:30 – 11:55</td>
<td>“An Introduction to Seromics: Autoantibodies in Cancer, Autoimmunity, and Beyond”</td>
<td>Tyler Hulett, PhD (CDI LABS)</td>
</tr>
<tr>
<td>11:55 – 12:20</td>
<td>“Using Radiomics as a Translational Endpoint” <em>(Pre-Recorded)</em></td>
<td>Prof. Eric Deutsch (Gustave Roussy Cancer Campus ~ Grand Paris)</td>
</tr>
<tr>
<td>12:20 – 12:45</td>
<td>“Lessons Learned from RTOG 1106, and Beyond”</td>
<td>Feng-Ming (Spring) Kong, MD, PhD (Hong Kong University)</td>
</tr>
<tr>
<td>12:45 – 1:00</td>
<td>General TS Project Updates &amp; Closing Remarks</td>
<td>Bo Lu, MD, PhD (Thomas Jefferson University)</td>
</tr>
<tr>
<td>NRG Main Member (Network)</td>
<td>CTEP ID</td>
<td>Accrued to NRG Studies and Credited to NRG</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>---------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>Allan Blair Cancer Centre</td>
<td>11076</td>
<td>2</td>
</tr>
<tr>
<td>Allegheny General Hospital</td>
<td>PA009</td>
<td>9</td>
</tr>
<tr>
<td>AMITA Health Alexian Brothers Medical Center</td>
<td>IL280</td>
<td>1</td>
</tr>
<tr>
<td>Arizona Center for Cancer Care-Peoria</td>
<td>AZ127</td>
<td>5</td>
</tr>
<tr>
<td>Aurora NCI Community Oncology Research Program</td>
<td>AURORA</td>
<td>11</td>
</tr>
<tr>
<td>Avera Cancer Institute</td>
<td>SD021</td>
<td>8</td>
</tr>
<tr>
<td>Banner University Medical Center - Tucson</td>
<td>AZ017</td>
<td>11</td>
</tr>
<tr>
<td>Baptist Health Cancer Research Network</td>
<td>BHCRCN</td>
<td>5</td>
</tr>
<tr>
<td>Baptist MD Anderson Cancer Center</td>
<td>FL003</td>
<td>1</td>
</tr>
<tr>
<td>Bay Area Tumor Institute NCORP</td>
<td>BATI</td>
<td>0</td>
</tr>
<tr>
<td>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</td>
<td>TX041</td>
<td>2</td>
</tr>
<tr>
<td>Baystate Medical Center</td>
<td>MA004</td>
<td>3</td>
</tr>
<tr>
<td>Berkshire Medical Center - Cancer Center</td>
<td>MA125</td>
<td>0</td>
</tr>
<tr>
<td>Boston Medical Center</td>
<td>MA043</td>
<td>1</td>
</tr>
<tr>
<td>Cancer Research Consortium of West Michigan NCORP</td>
<td>CRCWM</td>
<td>17</td>
</tr>
<tr>
<td>Cancer Research for the Ozarks NCORP</td>
<td>OZARKS</td>
<td>6</td>
</tr>
<tr>
<td>Cancer Research of Wisconsin and Northern Michigan Consortium</td>
<td>CROWN</td>
<td>28</td>
</tr>
<tr>
<td>Cancer Trials Ireland</td>
<td>ICORG</td>
<td>2</td>
</tr>
<tr>
<td>Carle Cancer Center NCI Community Oncology Research Program</td>
<td>CARLE</td>
<td>11</td>
</tr>
<tr>
<td>Carolinas Medical Center/Levine Cancer Institute</td>
<td>NC042</td>
<td>24</td>
</tr>
<tr>
<td>Cedars-Sinai Medical Center</td>
<td>CA016</td>
<td>2</td>
</tr>
<tr>
<td>Centre Hospitalier Universitaire de Sherbrooke-Fleurmont</td>
<td>11065</td>
<td>2</td>
</tr>
<tr>
<td>Chinese University of Hong Kong-Prince of Wales Hospital</td>
<td>34003</td>
<td>0</td>
</tr>
<tr>
<td>CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)</td>
<td>11073</td>
<td>1</td>
</tr>
<tr>
<td>CHUM - Centre Hospitalier de l'Universite de Montreal</td>
<td>11062</td>
<td>2</td>
</tr>
<tr>
<td>City of Hope Comprehensive Cancer Center</td>
<td>CA043</td>
<td>4</td>
</tr>
<tr>
<td>CIUSSSEMTL-Hopital Maisonneau-Rosemont</td>
<td>11060</td>
<td>1</td>
</tr>
<tr>
<td>Columbia University Minority Underserved NCORP</td>
<td>COLUMBIA</td>
<td>3</td>
</tr>
<tr>
<td>Columbus NCI Community Oncology Research Program</td>
<td>COLUMBUS</td>
<td>6</td>
</tr>
<tr>
<td>CommonSpirit Health Research Institute</td>
<td>CORA</td>
<td>9</td>
</tr>
<tr>
<td>Community Cancer Center North</td>
<td>IN006</td>
<td>0</td>
</tr>
<tr>
<td>Cooper Hospital University Medical Center</td>
<td>NJ036</td>
<td>7</td>
</tr>
<tr>
<td>Covenant Medical Center-Lakeside</td>
<td>TX054</td>
<td>0</td>
</tr>
<tr>
<td>Cross Cancer Institute</td>
<td>11132</td>
<td>0</td>
</tr>
<tr>
<td>CWRU Case Comprehensive Cancer Center LAPS</td>
<td>LAPS-OH029</td>
<td>60</td>
</tr>
<tr>
<td>Dana-Farber / Partners CancerCare LAPS</td>
<td>LAPS-MA036</td>
<td>12</td>
</tr>
<tr>
<td>Danbury Hospital</td>
<td>CT030</td>
<td>2</td>
</tr>
<tr>
<td>Dartmouth College - Norris Cotton Cancer Center LAPS</td>
<td>LAPS-NH012</td>
<td>11</td>
</tr>
<tr>
<td>Dayton NCI Community Oncology Research Program</td>
<td>DAYTON</td>
<td>0</td>
</tr>
<tr>
<td>Delaware/Christiana Care NCI Community Oncology Research Program</td>
<td>CHRISTIANA</td>
<td>21</td>
</tr>
<tr>
<td>Dell Seton Medical Center at The University of Texas</td>
<td>TX063</td>
<td>0</td>
</tr>
<tr>
<td>Duke University - Duke Cancer Institute LAPS</td>
<td>LAPS-NC010</td>
<td>2</td>
</tr>
<tr>
<td>Edward Hospital/Cancer Center</td>
<td>IL104</td>
<td>6</td>
</tr>
<tr>
<td>Institution</td>
<td>LAPS Code</td>
<td>C</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>-----------</td>
<td>---</td>
</tr>
<tr>
<td>Emory University - Winship Cancer Institute</td>
<td>LAPS-GA005</td>
<td>14</td>
</tr>
<tr>
<td>Essentia Health NCI Community Oncology Research Program</td>
<td>ESSENTIA</td>
<td>0</td>
</tr>
<tr>
<td>Fox Chase Cancer Center</td>
<td>PA086</td>
<td>4</td>
</tr>
<tr>
<td>Fred Hutchinson Cancer Research Center LAPS</td>
<td>LAPS-WA008</td>
<td>6</td>
</tr>
<tr>
<td>Froedtert and the Medical College of Wisconsin LAPS</td>
<td>LAPS-WIO13</td>
<td>17</td>
</tr>
<tr>
<td>Geisinger Cancer Institute NCI Community Oncology Research Program</td>
<td>GEISINGER</td>
<td>4</td>
</tr>
<tr>
<td>GenesisCare USA - Farmington Hills</td>
<td>MI310</td>
<td>23</td>
</tr>
<tr>
<td>Georgia Cares Minority Underserved NCORP</td>
<td>GACARES</td>
<td>4</td>
</tr>
<tr>
<td>Georgia NCI Community Oncology Research Program</td>
<td>GEORGIA</td>
<td>10</td>
</tr>
<tr>
<td>Greater Baltimore Medical Center</td>
<td>MD018</td>
<td>4</td>
</tr>
<tr>
<td>Gulf South Minority Underserved NCORP</td>
<td>GULFSOUTH</td>
<td>10</td>
</tr>
<tr>
<td>Hackensack University Medical Center</td>
<td>NJ022</td>
<td>4</td>
</tr>
<tr>
<td>Hartford Hospital</td>
<td>CT009</td>
<td>2</td>
</tr>
<tr>
<td>Hawaii Minority Underserved NCORP</td>
<td>HAWAII</td>
<td>2</td>
</tr>
<tr>
<td>Heartland Cancer Research NCORP</td>
<td>HEARTLAND</td>
<td>24</td>
</tr>
<tr>
<td>Henry Ford Hospital</td>
<td>MI026</td>
<td>8</td>
</tr>
<tr>
<td>Houston Methodist Hospital</td>
<td>TX036</td>
<td>4</td>
</tr>
<tr>
<td>Indiana University/Melvin and Bren Simon Cancer Center</td>
<td>IN007</td>
<td>13</td>
</tr>
<tr>
<td>Intermountain Medical Center</td>
<td>UT056</td>
<td>3</td>
</tr>
<tr>
<td>Iowa-Wide Oncology Research Coalition NCORP</td>
<td>IWORC</td>
<td>9</td>
</tr>
<tr>
<td>James A. Haley Veterans Affairs Hospital</td>
<td>FL064</td>
<td>0</td>
</tr>
<tr>
<td>Jewish General Hospital</td>
<td>11116</td>
<td>0</td>
</tr>
<tr>
<td>JHU Sidney Kimmel Comprehensive Cancer Center LAPS</td>
<td>LAPS-MD017</td>
<td>4</td>
</tr>
<tr>
<td>Juravinski Cancer Centre at Hamilton Health Sciences</td>
<td>11183</td>
<td>3</td>
</tr>
<tr>
<td>Kaiser Permanente NCI Community Oncology Research Program</td>
<td>KAISER</td>
<td>39</td>
</tr>
<tr>
<td>Kaiser Permanente-Gaithersburg Medical Center</td>
<td>MD198</td>
<td>0</td>
</tr>
<tr>
<td>Kantonsspital Aarau</td>
<td>67029</td>
<td>2</td>
</tr>
<tr>
<td>Lahey Hospital and Medical Center</td>
<td>MA017</td>
<td>1</td>
</tr>
<tr>
<td>Lankenau Medical Center</td>
<td>PA125</td>
<td>4</td>
</tr>
<tr>
<td>Legacy Good Samaritan Hospital and Medical Center</td>
<td>OR013</td>
<td>8</td>
</tr>
<tr>
<td>Loyola University Medical Center</td>
<td>IL017</td>
<td>2</td>
</tr>
<tr>
<td>Maine Health Cancer Care Network</td>
<td>MAINE</td>
<td>12</td>
</tr>
<tr>
<td>Mayo Clinic LAPS</td>
<td>LAPS-MN026</td>
<td>5</td>
</tr>
<tr>
<td>Medical University of South Carolina Minority Underserved NCORP</td>
<td>MUSC</td>
<td>13</td>
</tr>
<tr>
<td>MedStar Franklin Square Medical Center/Weinberg Cancer Institute</td>
<td>MD029</td>
<td>2</td>
</tr>
<tr>
<td>Memorial Sloan-Kettering Cancer Center LAPS</td>
<td>LAPS-NY016</td>
<td>31</td>
</tr>
<tr>
<td>Mercy Cancer Center - Sacramento</td>
<td>CA729</td>
<td>1</td>
</tr>
<tr>
<td>Metro Minnesota Community Oncology Research Consortium</td>
<td>METROMIN</td>
<td>49</td>
</tr>
<tr>
<td>Miami Cancer Institute</td>
<td>FL078</td>
<td>10</td>
</tr>
<tr>
<td>Michigan Cancer Research Consortium NCORP</td>
<td>MCRC</td>
<td>21</td>
</tr>
<tr>
<td>Michigan State University Clinical Center</td>
<td>MI038</td>
<td>0</td>
</tr>
<tr>
<td>Midwestern Regional Medical Center</td>
<td>IL120</td>
<td>2</td>
</tr>
<tr>
<td>Moffitt Cancer Center</td>
<td>FL065</td>
<td>5</td>
</tr>
<tr>
<td>Montana Cancer Consortium NCORP</td>
<td>MONTANA</td>
<td>13</td>
</tr>
<tr>
<td>Montefiore Minority Underserved NCORP</td>
<td>MONTEFIOR</td>
<td>5</td>
</tr>
<tr>
<td>Mount Sinai Hospital</td>
<td>NY021</td>
<td>8</td>
</tr>
<tr>
<td>National Cancer Centre Singapore</td>
<td>47005</td>
<td>1</td>
</tr>
<tr>
<td>National Institutes of Health Clinical Center</td>
<td>MD004</td>
<td>0</td>
</tr>
<tr>
<td>NCIORP of the Carolinas (Prisma Health NCORP)</td>
<td>GREENVILLE</td>
<td>4</td>
</tr>
<tr>
<td>Nebraska Methodist Hospital</td>
<td>NE007</td>
<td>2</td>
</tr>
<tr>
<td>Institution Name</td>
<td>Site Code</td>
<td>Year 2018</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>Nevada Cancer Research Foundation NCORP</td>
<td>NCRF</td>
<td>5</td>
</tr>
<tr>
<td>New Mexico Minority Underserved NCORP</td>
<td>NEWMEXICO</td>
<td>12</td>
</tr>
<tr>
<td>New York-Presbyterian/Brooklyn Methodist Hospital</td>
<td>NY075</td>
<td>14</td>
</tr>
<tr>
<td>NorthShore University HealthSystem-Evanston Hospital</td>
<td>IL018</td>
<td>9</td>
</tr>
<tr>
<td>Northwell Health NCORP</td>
<td>NORTHWELL</td>
<td>11</td>
</tr>
<tr>
<td>Northwestern University LAPS</td>
<td>LAPS-IL036</td>
<td>28</td>
</tr>
<tr>
<td>Norton Hospital Pavilion and Medical Campus</td>
<td>KY049</td>
<td>2</td>
</tr>
<tr>
<td>Odette Cancer Centre- Sunnybrook Health Sciences Centre</td>
<td>11118</td>
<td>13</td>
</tr>
<tr>
<td>Ohio State University Comprehensive Cancer Center LAPS</td>
<td>LAPS-OH007</td>
<td>12</td>
</tr>
<tr>
<td>Orlando Health Cancer Institute</td>
<td>FL020</td>
<td>3</td>
</tr>
<tr>
<td>Ottawa Hospital and Cancer Center-General Campus</td>
<td>11025</td>
<td>14</td>
</tr>
<tr>
<td>Pacific Cancer Research Consortium NCORP</td>
<td>PCRC</td>
<td>28</td>
</tr>
<tr>
<td>Parkview Regional Medical Center</td>
<td>IN181</td>
<td>2</td>
</tr>
<tr>
<td>Penn State Milton S Hershey Medical Center</td>
<td>PA042</td>
<td>8</td>
</tr>
<tr>
<td>Peter MacCallum Cancer Centre</td>
<td>3003</td>
<td>0</td>
</tr>
<tr>
<td>Piedmont Hospital</td>
<td>GA027</td>
<td>2</td>
</tr>
<tr>
<td>ProMedica Flower Hospital</td>
<td>OHO12</td>
<td>4</td>
</tr>
<tr>
<td>Puerto Rico Minority Underserved NCORP</td>
<td>PUERTORICO</td>
<td>11</td>
</tr>
<tr>
<td>Reading Hospital</td>
<td>PA107</td>
<td>10</td>
</tr>
<tr>
<td>Rhode Island Hospital</td>
<td>R1005</td>
<td>0</td>
</tr>
<tr>
<td>Roswell Park Cancer Institute LAPS</td>
<td>LAPS-NY158</td>
<td>14</td>
</tr>
<tr>
<td>Rush University Medical Center</td>
<td>IL043</td>
<td>2</td>
</tr>
<tr>
<td>Rutgers Cancer Institute of New Jersey</td>
<td>NJ066</td>
<td>11</td>
</tr>
<tr>
<td>Saint Joseph Hospital - Orange</td>
<td>CA087</td>
<td>0</td>
</tr>
<tr>
<td>Saint Joseph’s Hospital and Medical Center</td>
<td>AZ099</td>
<td>0</td>
</tr>
<tr>
<td>Saitama Medical University International Medical Center</td>
<td>42061</td>
<td>15</td>
</tr>
<tr>
<td>Sanford NCI Community Oncology Research Program of the North Cen</td>
<td>SANFORD</td>
<td>2</td>
</tr>
<tr>
<td>Saskatoon Cancer Centre</td>
<td>11120</td>
<td>8</td>
</tr>
<tr>
<td>Seoul National University Hospital</td>
<td>43002</td>
<td>3</td>
</tr>
<tr>
<td>Southeast Clinical Oncology Research Consortium NCORP</td>
<td>SCOR</td>
<td>19</td>
</tr>
<tr>
<td>Stanford Cancer Institute Palo Alto</td>
<td>CA141</td>
<td>9</td>
</tr>
<tr>
<td>Stony Brook University Medical Center</td>
<td>NY184</td>
<td>7</td>
</tr>
<tr>
<td>Stroger Hospital of Cook County Minority Underserved NCORP</td>
<td>STROGER</td>
<td>0</td>
</tr>
<tr>
<td>Summa Health System - Akron Campus</td>
<td>OHO55</td>
<td>2</td>
</tr>
<tr>
<td>Sun Yat-sen University Cancer Center</td>
<td>60021</td>
<td>5</td>
</tr>
<tr>
<td>Sutter Cancer Research Consortium</td>
<td>SUTTER</td>
<td>4</td>
</tr>
<tr>
<td>The James Graham Brown Cancer Center at University of Louisville</td>
<td>KY002</td>
<td>7</td>
</tr>
<tr>
<td>The Research Institute of the McGill University Health Centre (MUHC)</td>
<td>11318</td>
<td>2</td>
</tr>
<tr>
<td>Thomas Jefferson University Hospital LAPS</td>
<td>LAPS-PA121</td>
<td>17</td>
</tr>
<tr>
<td>Thompson Cancer Survival Center</td>
<td>TN038</td>
<td>3</td>
</tr>
<tr>
<td>Tibor Rubin VA Medical Center</td>
<td>CA041</td>
<td>0</td>
</tr>
<tr>
<td>Tom Baker Cancer Centre</td>
<td>11134</td>
<td>3</td>
</tr>
<tr>
<td>Trinity Cancer Care Center</td>
<td>ND026</td>
<td>0</td>
</tr>
<tr>
<td>Tulane University Health Sciences Center</td>
<td>LA001</td>
<td>1</td>
</tr>
<tr>
<td>UC Davis Comprehensive Cancer Center LAPS</td>
<td>LAPS-CA189</td>
<td>5</td>
</tr>
<tr>
<td>UC Irvine Health/Chao Family Comprehensive Cancer Center</td>
<td>CA088</td>
<td>4</td>
</tr>
<tr>
<td>UC San Diego Moores Cancer Center</td>
<td>CA249</td>
<td>9</td>
</tr>
<tr>
<td>UCLA / Jonsson Comprehensive Cancer Center</td>
<td>CA006</td>
<td>2</td>
</tr>
<tr>
<td>UCSF Medical Center-Mount Zion</td>
<td>CA136</td>
<td>9</td>
</tr>
<tr>
<td>UNC Lineberger Comprehensive Cancer Center LAPS</td>
<td>LAPS-NC007</td>
<td>3</td>
</tr>
</tbody>
</table>
NRG Oncology would like to recognize and thank its commercial supporters for independent medical educational support associated with the NRG Oncology Summer Meeting.

GSK
Immunogen
Seagen
NRG Oncology
Summer 2022 Hybrid-Meeting
Sponsors and Exhibitors

Exhibitors

Eisai
Caris Life Sciences
Castle Biosciences
Merck
IROC

Sponsors

Castle Biosciences
GlaxoSmithKline (GSK)
Mersana

NRG Oncology would like to recognize and thank its commercial supporters for independent support associated with the NRG Oncology Summer 2022 Hybrid Meeting.
Exhibitors

Increase awareness of our human health care (hhc) mission. We give your first thought to patients and their families. We have a passionate commitment to patient care that is a driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Caris Life Sciences is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. With a primary focus on cancer, Caris suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. To learn more, please visit www.CarisLifeSciences.com.

Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions. From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed (castletestinfo.com).

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

The Imaging and Radiation Oncology Core (IROC) provides integrated radiation oncology and diagnostic imaging quality control programs in support of clinical trials conducted by NRG Oncology and the other Network Groups in the National Clinical Trials Network. IROC staff are here to answer study data submission related radiation therapy and diagnostic Imaging questions from investigators or other research professionals.

Please take the time to visit the exhibit booths located in: Grand MN/Ballroom/East

Exhibit Hours are:
Friday, July 22, 2022 - 7 am - 5 pm
Saturday, July 23, 2022 - 7 am - 1 pm

Complimentary coffee, tea and soft drinks will be served in the exhibit area at specified times on each day that exhibits are open.
Sponsors

Platinum Sponsor

Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions. From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed (castletestinfo.com).

Silver Sponsors

GSK unites science technology and talent to get ahead of disease together. We prevent and treat disease with vaccines, specialty, and general medicines.

Mersana Therapeutics is a clinical -stage biopharmaceutical company using its ADC platforms to rapidly develop novel ADCs with optimal efficiency, safety, and tolerability to improve the lives of people fighting cancer.
At Eisai, everything we do is guided by a simple principle: patients and their families come first. We spend time with them. We listen and we learn about their lives, their desires and their greatest needs. We call this human health care or hhc, giving first thoughts to patients and their families and helping increase the benefits health care provides.

Our hhc mission is what drives us to discover innovative solutions and therapies that help address unmet needs within the communities that we seek to serve.

Eisai is proud to support the NRG Oncology Meeting.

hhc
human health care

TO LEARN MORE, PLEASE VISIT WWW.EISAI.COM/US
GUIDED BY INNOVATION.

Castle Biosciences is proud to support the NRG with innovative approaches to improve patient care. Together we help the next generation of physicians push the boundaries of what’s possible. Driven by a shared purpose, we are transforming the treatment of dermatological cancers, enabling more precise testing for better informed decisions.

CastleTestInfo.com
FUTURE DATES AND LOCATIONS
NRG ONCOLOGY MEETINGS

JANUARY 26-28, 2023
ORLANDO, FLORIDA

JULY 20-22, 2023
PHILADELPHIA, PENNSYLVANIA

FEBRUARY 15-17, 2024
ORLANDO, FLORIDA